<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anthracycline‐containing regimens for treatment of follicular lymphoma in adults - Itchaki, G - 2013 | Cochrane Library</title> <meta content="Anthracycline‐containing regimens for treatment of follicular lymphoma in adults - Itchaki, G - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008909.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anthracycline‐containing regimens for treatment of follicular lymphoma in adults - Itchaki, G - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008909.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008909.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Anthracycline‐containing regimens for treatment of follicular lymphoma in adults" name="citation_title"/> <meta content="Gilad Itchaki" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="giladi@clalit.org.il" name="citation_author_email"/> <meta content="Anat Gafter‐Gvili" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Meir Lahav" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Liat Vidal" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Pia Raanani" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Ofer Shpilberg" name="citation_author"/> <meta content="Beilinson Hospital, Rabin Medical Center" name="citation_author_institution"/> <meta content="Mical Paul" name="citation_author"/> <meta content="Rambam Health Care Center. Haifa, Israel and Sackler Faculty of Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD008909.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/07/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008909.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008909.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008909.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anthracyclines [*therapeutic use]; Antibiotics, Antineoplastic [*therapeutic use]; Antibodies, Monoclonal, Murine‐Derived [therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Induction Chemotherapy [methods]; Lymphoma, Follicular [*drug therapy, mortality, pathology]; Maintenance Chemotherapy [methods]; Randomized Controlled Trials as Topic; Rituximab" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008909.pub2&amp;doi=10.1002/14651858.CD008909.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008909\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008909\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008909.pub2",title:"Anthracycline\\u2010containing regimens for treatment of follicular lymphoma in adults",firstPublishedDate:"Jul 7, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008909.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008909.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008909.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008909.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008909.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008909.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008909.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008909.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008909.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008909.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>811 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008909.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/appendices#CD008909-sec-0086"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/table_n/CD008909StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/table_n/CD008909StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anthracycline‐containing regimens for treatment of follicular lymphoma in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#CD008909-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Gilad Itchaki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#CD008909-cr-0003">Anat Gafter‐Gvili</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#CD008909-cr-0004">Meir Lahav</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#CD008909-cr-0005">Liat Vidal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#CD008909-cr-0006">Pia Raanani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#CD008909-cr-0007">Ofer Shpilberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information#CD008909-cr-0008">Mical Paul</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information/en#CD008909-sec-0090">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 July 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008909.pub2">https://doi.org/10.1002/14651858.CD008909.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008909-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008909-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008909-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008909-abs-0005">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008909-abs-0001" lang="en"> <section id="CD008909-sec-0001"> <h3 class="title" id="CD008909-sec-0001">Background</h3> <p>Anthracycline‐containing regimens (ACR) are the most prevalent regimens in the management of patients with advanced follicular lymphoma (FL). However, there is no proof that they are superior to non‐anthracycline‐containing regimens (non‐ACR). </p> </section> <section id="CD008909-sec-0002"> <h3 class="title" id="CD008909-sec-0002">Objectives</h3> <p>To compare the efficacy of ACRs to other chemotherapy regimens, in the treatment of FL. </p> </section> <section id="CD008909-sec-0003"> <h3 class="title" id="CD008909-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2013, Issue 3), MEDLINE (January 1966 to April 2013), smaller databases, relevant conference proceedings (2004 to 2012) and the National Medical Library (April 2013). </p> </section> <section id="CD008909-sec-0004"> <h3 class="title" id="CD008909-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) comparing ACR with non‐ACR for adult patients with FL. We excluded trials in which immunotherapy, radiotherapy alone or stem‐cell transplantation were used in one arm alone. Our primary outcome was overall survival (OS). Secondary outcomes included disease control, as measured by progression‐free survival (PFS) or remission duration (RD). </p> </section> <section id="CD008909-sec-0005"> <h3 class="title" id="CD008909-sec-0005">Data collection and analysis</h3> <p>Two review authors assessed the quality of trials and extracted data. We contacted study authors for additional information. We analyzed trials separately according to resemblance of the chemotherapeutic regimens in study arms, other than the addition of anthracyclines ('same' versus 'different' chemotherapy). Hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI) were estimated and pooled using the fixed‐effect model. </p> </section> <section id="CD008909-sec-0006"> <h3 class="title" id="CD008909-sec-0006">Main results</h3> <p>Eight RCTs, conducted between 1974 and 2011, and involving 2636 patients were included in this meta‐analysis. All trials included therapy‐naive patients. Rituximab was used in one trial only. Follow‐up was between three and five years in most trials (range three to 18 years). All trials were published in peer‐reviewed journals. </p> <p>Five trials compared similar chemotherapeutic regimens, except for the anthracycline. In three studies reporting overall survival specifically in FL patients, there was no statistically significant difference between ACR and non‐ACR arms (HR 0.99; 95% CI 0.77 to 1.29; I<sup>2</sup> = 0%). ACR significantly improved disease control (HR 0.65; 95% CI 0.52 to 0.81; four trials). Progression or relapse at three years were reduced (RR 0.73; 95% CI 0.63 to 0.85). Anthracyclines did not significantly increase rates of complete response (RR 1.05; 95% CI 0.94 to 1.18) or overall response (RR 1.06; 95% CI 1.00 to 1.12), but heterogeneity was substantial. </p> <p>Overall, ACR were more often associated with cytopenias, but not with serious infections or death related to chemotherapy. Cardiotoxicity, albeit rare, was associated with anthracycline use (RR 4.55; 95% CI 0.92 to 22.49; four trials). </p> <p>Three trials added anthracycline to one arm of two different regimens. None showed benefit to ACR regarding OS, yet there was a trend in favor of anthracyclines for disease control. Results were heterogeneous. </p> <p>We judged the overall quality of these trials as moderate as all are unblinded, some are outdated and are not uniform in outcome definitions. </p> </section> <section id="CD008909-sec-0007"> <h3 class="title" id="CD008909-sec-0007">Authors' conclusions</h3> <p>The use of anthracyclines in patients with FL has no demonstrable benefit on overall survival, although it may have been mitigated by the more intense regimens given in the control arms of three of five trials. ACR improved disease control, as measured by PFS and RD with an increased risk for side effects, notably cardiotoxicity. The current evidence on the added value of ACR in the management of FL is limited. Further studies involving immunotherapy during induction and maintenance may change conclusion. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008909-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008909-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008909-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008909-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008909-abs-0003" lang="en"> <h3>Anthracyclines in the treatment of follicular lymphoma (FL) in adults</h3> <p>FL is the most common indolent non‐Hodgkin's lymphoma (NHL). It is a slowly progressive disease, with a risk of transformation to a more aggressive lymphoma. Advanced disease (stage III and IV) has been considered incurable. However, in recent years, the use of combination therapy and treatment with the monoclonal anti‐CD20 antibody rituximab, have prolonged survival and decreased transformation rate, and is now considered standard of care in FL patients. One of the most common chemotherapies used in the treatment of FL is the combination of rituximab with cyclophosphamide, vincristine, adriamycin, prednisone (R‐CHOP), which contains an anthracycline (adriamycin). Other anthracycline‐containing regimens (ACR) have also been used to treat FL patients. However, there is no proof that ACRs are better than non‐anthracycline‐containing regimens (non‐ACRs), and there are no standard guidelines for the initial treatment of advanced FL. Importantly, anthracyclines have serious side effects, notably a decrease in blood counts and potential damage to the heart, depending on the dose. </p> <p>The aim of this systematic review and meta‐analysis was to examine if there is a benefit in the use of anthracyclines for patients with FL. We looked at overall survival (OS); measures of disease control; response rates; and side effects. </p> <p>We found eight randomized controlled trials, of which five compared similar chemotherapy regimens in both trial arms, except for the anthracycline. Even among these five trials, three included more intense chemotherapy in the control arm. Most trials were conducted in the 1980s and 1990s. Only one of them included rituximab as part of the chemotherapy regimen. Almost all patients were treatment‐naive with advanced disease. Follow‐up ranged between three and five years in most trials. The main results from this set of trials are. </p> <p>1. There is no evidence that OS is prolonged with the use of anthracyclines, although it may have been hampered by the more intense regimens given in the control arms of three of five trials. </p> <p>2. Anthracyclines improved disease control. Concordantly, less patients progressed or relapsed within three years of treatment with ACR. </p> <p>3. There is no statistically significant difference in complete or overall response rates. </p> <p>4. Qualitatively, more side effects were reported with ACR, myelotoxicity and cardiotoxicity included. </p> <p>This evidence is limited, mainly due to disparities in regimens between control and study arms, but also since most included trials were conducted over one to two decades ago, and only one employed rituximab. Importantly, results from this study were in agreement with pooled‐outcomes from trials of the pre‐rituximab era. </p> <p>It is essential to find the optimal chemotherapeutic regimen in conjunction with rituximab and other novel agents, and understand the role of anthracyclines in this combination, especially with current methods that are able to reduce their toxicity. With longer follow‐up periods we may better understand whether improved disease control will eventually translate to an increase in survival. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008909-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008909-sec-0081"></div> <h3 class="title" id="CD008909-sec-0082">Implications for practice</h3> <section id="CD008909-sec-0082"> <p>ACR, regardless of the chemotherapeutic regimen, increased PFS and RD, in first‐line treatment of advanced, low‐grade FL patients. There was no notable effect on OS, although disparities in regimens might weaken this result, in favour for ACR. Evidence is of moderate quality. </p> <p>In an indolent disease with a remitting and relapsing long‐term course, importance of PFS prolongation needs to be considered, especially in light of increased toxicity with ACR. </p> </section> <h3 class="title" id="CD008909-sec-0083">Implications for research</h3> <section id="CD008909-sec-0083"> <p>The role of anthracyclines in conjunction with immunotherapy needs to be elucidated in a large‐scale RCT. There are a few ongoing trials comparing R‐CHOP with R‐CVP or with other regimens, and they are most likely to answer this important question. RCTs assessing the role of anthracyclines for early‐disease, high‐grade FL or as second‐line treatment are needed. Prospective trials with long follow‐up periods (of 10 years or more) are needed in order to assess OS benefit in FL patients adequately. In addition, the effect of ACR on molecular remission, and its importance as a response measure requires investigation. </p> <p>The efficacy and adverse events rate of various non‐doxorubicin ACR should be investigated, especially in more frail populations. However, the availability of novel and efficacious biologic agents makes it unlikely that new resources will be invested. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008909-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008909-sec-0015"></div> <div class="table" id="CD008909-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ACR compared to non‐ACR for treatment of follicular lymphoma in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ACR compared to non‐ACR for treatment of follicular lymphoma in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults receiving treatment for follicular lymphoma<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Aanthracycline<br/> <b>Comparison:</b> no anthracycline same chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No anthracycline same chemotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Anthracycline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> number of dead patients<br/> Follow‐up: median 50 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b> <br/> (449 to 631) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.99</b> <br/> (0.77 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality at 3 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> <br/> (174 to 327) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> <br/> (0.67 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>839 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>889 per 1000</b> <br/> (839 to 940) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> <br/> (1 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease control</b> <br/> number of patients with progression<br/> Follow‐up: median 30 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>356 per 1000</b> <br/> (297 to 423) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.65</b> <br/> (0.52 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>759<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression/relapse at 3 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>544 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>397 per 1000</b> <br/> (343 to 463) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.73</b> <br/> (0.63 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neutropenia grade 3‐4</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b> <br/> (277 to 485) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.94</b> <br/> (1.46 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>533<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiotoxicity**</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> <br/> (2 to 40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.55</b> <br/> (0.92 to 22.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1412<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Includes all trials, irrespectively of the comparison ("same chemotherapy"; "different chemotherapy").<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Small number of events<br/> <sup>2</sup> Moderate heterogeneity<br/> <sup>3</sup> Different reporting methods<br/> <sup>4</sup> Not consistently reported<br/> <sup>5</sup> Wide confidence interval </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008909-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008909-sec-0016"></div> <section id="CD008909-sec-0017"> <h3 class="title" id="CD008909-sec-0017">Description of the condition</h3> <p>Follicular lymphoma (FL) is the most common indolent and the second most common non‐Hodgkin lymphoma (NHL) subtype in the Western world. It constitutes up to 30% of all NHL (<a href="./references#CD008909-bbs2-0076" title="NHLCP . A clinical evaluation of the International Lymphoma Study Group classification of non‐Hodgkin's lymphoma. The Non‐Hodgkin's Lymphoma Classification Project. Blood1997;89(11):3909‐18. ">NHLCP 1997</a>), and its incidence has risen in the last decades and is currently 3.3 to 3.8 cases per 100,000 patient‐years, in the white US population (<a href="./references#CD008909-bbs2-0074" title="MortonLM , WangSS , DevesaSS , HartgeP , WeisenburgerDD , LinetMS . Lymphoma incidence patterns by WHO subtype in the United States, 1992‐2001. Blood2006;107(1):265‐76. ">Morton 2006</a>). It is defined as a group of malignancies composed of follicle center cells, usually a mixture of centrocytes (cleaved cells) and centroblasts (large non‐cleaved cells) (<a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>). </p> <p>The Revised European‐American Classification of Lymphoid Neoplasms (REAL classification) (<a href="./references#CD008909-bbs2-0065" title="HarrisNL , JaffeES , SteinH , BanksPM , ChanJK , ClearyML , et al. A Revised European‐American classification of Lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood1994;84(5):1361‐92. ">Harris 1994</a>), and more recently the updated World Health Organization (WHO) classification (<a href="./references#CD008909-bbs2-0066" title="HarrisNL , JaffeES , DieboldJ , FlandrinG , Muller‐HermelinkHK , VardimanJ , et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting‐Airlie House, Virginia, November 1997. Journal of Clinical Oncology1999;17(12):3835‐49. ">Harris 1999</a>; <a href="./references#CD008909-bbs2-0087" title="SwerdlowSH , CampoE , HarrisNL , JaffeES , PileriSA , SteinH , et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Vol. 2, Lyon, France: IARC Press, 2008. ">Swerdlow 2008</a>) propose the term follicle center lymphoma, and divide it into grades 1, 2, 3a, and 3b. The grades are distinguished by the presence of predominantly small, mixed small and large, and large cells, respectively. Pathologically, according to the 'Berard Criteria', the grades are defined by the number of centroblasts per high power field (<a href="./references#CD008909-bbs2-0071" title="MannRB , BerardCW . Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematology and Oncology1983;1(2):187‐92. ">Mann 1983</a>). In grade 3a centrocytes are still present, while grade 3b involves centroblasts only. Grade 3 FL is biologically distinct from grades 1 and 2 in its clinical behavior and response to chemotherapy and is treated as aggressive lymphoma. Owing to imprecision in differentiating between grade 3a and 3b, its relative infrequency, and the nature of the trials involved, it is difficult to assess its natural history. Yet, some consider FL grades 1, 2, 3a as a single histologic entity, and keep it apart from grade 3b, which is treated closely to diffuse large B‐cell lymphoma (<a href="./references#CD008909-bbs2-0055" title="ChauI , JonesR , CunninghamD , WotherspoonA , MaiseyN , NormanAR , et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front‐line therapy?. British Journal of Cancer2003;89(1):36‐42. ">Chau 2003</a>; <a href="./references#CD008909-bbs2-0062" title="GantiAK , WeisenburgerDD , SmithLM , HansCP , BociekRG , BiermanPJ , et al. Patients with grade 3 follicular lymphoma have prolonged relapse‐free survival following anthracycline‐based chemotherapy: the Nebraska Lymphoma Study Group Experience. Annals of Oncology2006;17(6):920‐7. ">Ganti 2006</a>; <a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>). FL encompasses most malignancies previously classified as nodular lymphoma in the Working Formulation, most tumors classified as follicular center cell lymphoma in the Lukes‐Collins classification, and all cases in Kiel classification category of centroblastic/centrocytic (CB/CC) follicular or follicular CB lymphoma (<a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>). </p> <p>The molecular hallmark of FL is the acquisition of translocation t(14;18) by pre‐B cells during an abnormal immunoglobulin rearrangement in the bone marrow, and the overexpression of bcl2 protein, which protects cells from apoptosis (<a href="./references#CD008909-bbs2-0051" title="BendandiM . Aiming at a curative strategy for follicular lymphoma. CA: A Cancer Journal for Clinicians2008;58(5):305‐17. ">Bendandi 2008</a>). However, only 70% to 95% of FL patients are t(14;18) positive (<a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>), and t(14;18)‐positive cells may also be found in healthy individuals and patients with other malignancies. Staging of FL is done according to the Ann Arbor system, according to number of involved lymph‐node regions, presence of extra‐lymphatic involvement, and presence of B symptoms. Stages I/II are considered early disease, while stages III/IV are considered advanced. Advanced disease is present in more than 80% of FL patients, and bone marrow involvement in more than 60% (<a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>). </p> <p>Contemporary scoring systems specific for FL are the Italian Lymphoma Intergroup Index (ILI) (<a href="./references#CD008909-bbs2-0059" title="FedericoM , VitoloU , ZinzaniPL , ChisesiT , CloV , BellesiG , et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood2000;95(3):783‐9. ">Federico 2000</a>) and the more widely accepted Follicular Lymphoma International Prognostic Index (FLIPI) (<a href="./references#CD008909-bbs2-0086" title="Solal‐CelignyP , RoyP , ColombatP , WhiteJ , ArmitageJO , Arranz‐SaezR , et al. Follicular lymphoma international prognostic index. Blood2004;104(5):1258‐65. ">Solal‐Celigny 2004</a>). The FLIPI designates prognostic groups as having low, intermediate, or high risk based on the presence or absence of five adverse prognostic factors: age &gt; 60 years, Ann Arbor stage III/IV, hemoglobin level &lt; 12 g/dL, involvement of more than four nodal sites, and elevated serum lactate dehydrogenase (LDH) level. The risk of transformation is higher in patients with advanced stage and higher FLIPI. Another scoring system was offered by the same group, FLIPI2, which is intended to stratify risk in the era of immunotherapy, and takes progression‐free survival (PFS) as the principal outcome measure. It takes into account β<sub>2</sub>‐microglobulin higher than the upper limit of normal, longest diameter of the largest involved node longer than 6 cm, bone marrow involvement, hemoglobin level lower than 12 g/dL, and age older than 60 years (<a href="./references#CD008909-bbs2-0060" title="FedericoM , BelleiM , MarcheselliL , LuminariS , Lopez‐GuillermoA , VitoloU , et al. Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of Clinical Oncology2009;27(27):4555‐62. ">Federico 2009</a>). FL has had over the years a median survival of eight to 10 years. Its course is largely unpredictable, and it may undergo more aggressive histologic and clinical transformation to aggressive lymphoma at a rate of 3% per year (<a href="./references#CD008909-bbs2-0051" title="BendandiM . Aiming at a curative strategy for follicular lymphoma. CA: A Cancer Journal for Clinicians2008;58(5):305‐17. ">Bendandi 2008</a>), which is usually poorly responsive to chemotherapy. The median survival from transformation is about one year (<a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>).  </p> <p>Treatment for FL is considered separately for early‐stage versus advanced‐stage disease and for newly diagnosed versus relapsed or resistant disease. Historically, advanced FL was considered incurable, with no difference in overall survival (OS) between early treatment and 'watch and wait' approach, and with relapse as a rule (<a href="./references#CD008909-bbs2-0051" title="BendandiM . Aiming at a curative strategy for follicular lymphoma. CA: A Cancer Journal for Clinicians2008;58(5):305‐17. ">Bendandi 2008</a>). However, in recent years, new treatment approaches, and specifically the introduction of rituximab (a monoclonal anti‐CD20 antibody), have decreased transformation rate (<a href="./references#CD008909-bbs2-0073" title="MontotoS , DaviesAJ , MatthewsJ , CalaminiciM , NortonAJ , AmessJ , et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B‐cell lymphoma. Journal of Clinical Oncology2007;25(17):2426‐33. ">Montoto 2007</a>) and improved survival (<a href="./references#CD008909-bbs2-0089" title="TillyH , ZelenetzA . Treatment of follicular lymphoma: current status. Leukemia &amp; Lymphoma2008;49 Suppl 1:7‐17. ">Tilly 2008</a>). Thus, the first challenge, especially in newly diagnosed patients with FL, is distinguishing those most likely to benefit from an aggressive, curative‐intent approach. </p> <p>Early‐stage FL is curable in 30% to 40% of patients, and is usually treated with localized radiotherapy, with even better results with combined‐modality therapy (<a href="./references#CD008909-bbs2-0051" title="BendandiM . Aiming at a curative strategy for follicular lymphoma. CA: A Cancer Journal for Clinicians2008;58(5):305‐17. ">Bendandi 2008</a>), especially in patients with high tumor burden (<a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>). In newly diagnosed advanced FL, observation is still an option, especially in high‐risk patients and provided there are no high tumor burden features (<a href="./references#CD008909-bbs2-0068" title="HorningSJ , RosenbergSA . The natural history of initially untreated low‐grade non‐Hodgkin's lymphomas. New England Journal of Medicine1984;311(23):1471‐5. ">Horning 1984</a>). In this case, usual indications for treatment in advanced FL are symptomatic disease, hematopoietic impairment, bulky disease, or rapid lymphoma progression. Specific criteria have been established to guide initiation of therapy, such as the Groupe d'Etute des Lymphomes Folliculire (GELF) criteria (<a href="./references#CD008909-bbs2-0085" title="Solal‐CelignyP , LepageE , BrousseN , ReyesF , HaiounC , LeporrierM , et al. Recombinant interferon alfa‐2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. New England Journal of Medicine1993;329(22):1608‐14. ">Solal‐Celigny 1993</a>). However, at least in principal, eradication should be the initial goal in the management of most patients. In relapsing or resistant FL, salvage therapy includes chemoimmunotherapy regimens not used in first‐line therapy, radioimmunotherapy and stem‐cell transplantation (SCT) (<a href="./references#CD008909-bbs2-0051" title="BendandiM . Aiming at a curative strategy for follicular lymphoma. CA: A Cancer Journal for Clinicians2008;58(5):305‐17. ">Bendandi 2008</a>; <a href="./references#CD008909-bbs2-0064" title="GrebA , BohliusJ , SchieferD , SchwarzerG , SchulzH , EngertA . High‐dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non‐Hodgkin Lymphoma (NHL) in adults. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004024.pub2] ">Greb 2008</a>; <a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>). </p> <p>There are no standard guidelines for the initial treatment of advanced FL. The choice of chemotherapy largely depends on many factors such as: patient's age and performance status, comorbidity, the pace of disease, and the aim of the treatment (i.e. palliation or attempt to cure). Chemotherapy regimens may include: alkylating agents, anthracycline‐based chemotherapies, purine analogs, and regimens resembling the cyclophosphamide, vincristine, prednisone (CVP)‐like regimens (<a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>). The combination of rituximab with nearly any chemotherapy regimen is superior to the same chemotherapy regimen alone (<a href="./references#CD008909-bbs2-0089" title="TillyH , ZelenetzA . Treatment of follicular lymphoma: current status. Leukemia &amp; Lymphoma2008;49 Suppl 1:7‐17. ">Tilly 2008</a>) as was shown in many randomized trials, and summarized in a meta‐analysis published in <i>The Cochrane Library</i> (<a href="./references#CD008909-bbs2-0083" title="SchulzH , BohliusJ , SkoetzN , TrelleS , KoberT , ReiserM , et al. Chemotherapy plus Rituximab versus chemotherapy alone for B‐cell non‐Hodgkin's lymphoma. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003805.pub2] ">Schulz 2007</a>). Thus, the concomitant administration of rituximab and a chemotherapy regimen has rapidly become the first‐line standard of treatment in FL. It also has a role in maintenance therapy as well as in relapsed, recurrent, or resistant patients (<a href="./references#CD008909-bbs2-0091" title="VidalL , Gafter‐GviliA , LeiboviciL , ShpilbergO . Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006552.pub2] ">Vidal 2009</a>). According to the National LymphoCare Study (NLCS), most FL patients in the US (regardless of staging) were treated by chemotherapy and rituximab combination, 55% of whom with rituximab, cyclophosphamide, vincristine, adriamycin, prednisone (R‐CHOP) regimen, 23% with R‐CVP, and 15% with fludarabine‐based regimens (<a href="./references#CD008909-bbs2-0061" title="FriedbergJW , TaylorMD , CerhanJR , FlowersCR , DillonH , FarberCM , et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. Journal of Clinical Oncology2009;27(8):1202‐8. ">Friedberg 2009</a>). High‐dose chemotherapy followed by autologous SCT is still a controversial modality in first‐line treatment of FL. </p> <p>Response to therapy is monitored through history, physical examination, computed tomography (CT) or fluorodeoxyglucose positron emission tomography (FDG‐PET), and bone marrow biopsy in some patients. Complete response (CR) has been achieved when: there is no clinical evidence of disease or disease‐related symptoms; all lymph nodes are normal sized on CT scan; spleen and liver are non‐palpable and without nodules; previously involved bone marrow is negative on repeat biopsy. Partial response (PR) is defined as decrease in nodal size by at least 50% and no progression otherwise (<a href="./references#CD008909-bbs2-0056" title="ChesonBD , HorningSJ , CoiffierB , ShippMA , FisherRI , ConnorsJM , et al. Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology1999;17(4):1244. ">Cheson 1999</a>; <a href="./references#CD008909-bbs2-0057" title="ChesonBD , PfistnerB , JuweidME , GascoyneRD , SpechtL , HorningSJ , et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology2007;25(5):579‐86. ">Cheson 2007</a>). These patients are treated as refractory disease. Molecular response, detecting minimal residual disease, by using polymerase chain reaction (PCR) for bcl‐2/IgH translocation and clonally rearranged IgH genes, correlates well with outcome as shown by several prospective studies. However, it is still unclear whether eradicating the t(14;18)‐bearing clone is an important goal of therapy, and is not routinely performed (<a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>). </p> </section> <section id="CD008909-sec-0018"> <h3 class="title" id="CD008909-sec-0018">Description of the intervention</h3> <p>We are going to assess the role of anthracyclines in the treatment of FL.  </p> <p>Anthracyclines are antibiotic drugs that are among the most important antitumor agents. They include doxorubicin (adriamycin) and daunorubicin, and the analogous idarubicin and epirubicin. Mitoxantrone is an anthracenedione, but is practically considered in this group. These drugs intercalate with deoxyribonucleic acid (DNA), directly affecting transcription and replication. Moreover, they form a tripartite complex with topoisomerase II and DNA, and inhibit the religation of broken DNA strands leading to apoptosis. They also generate free radicals that damage DNA (<a href="./references#CD008909-bbs2-0063" title="GoodmanLS , GilmanA , BruntonLL , LazoJS , ParkerKL . Goodman &amp; Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw‐Hill, 2006. ">Goodman 2006</a>).  </p> <p>The toxic manifestations of these agents include: myelotoxicity; stomatitis; alopecia; gastrointestinal (GI) disturbances; and dermatological manifestations such as 'adriamycin flare' at the site of injection, facial flushing, conjunctivitis, and lacrimation. Cardiac toxicity is a unique and the most important adverse event. Two types of cardiomyopathy may occur. An acute form, develops within 24 hours of treatment, and is characterized by abnormal electrocardiogram (ECG) findings and even transient reduction in ejection fraction, elevation of troponin, and pericardial effusion. A subacute/chronic, cumulative dose‐related toxicity (usually above 550 mg/m<sup>2</sup>) is manifested as congestive heart failure. Its incidence ranges widely, but is approximately 7.5% at a cumulative dose above 550 mg/m<sup>2</sup>. Elderly people, females, children and patients with a history of cardiac disease are at increased risk, as are patients treated with chest irradiation, and with the administration of high‐dose cyclophosphamide or another anthracycline, and concomitant trastuzumab or paclitaxel (<a href="./references#CD008909-bbs2-0078" title="OutomuroD , GranaDR , AzzatoF , MileiJ . Adriamycin‐induced myocardial toxicity: new solutions for an old problem?. International Journal of Cardiology2007;117(1):6‐15. ">Outomuro 2007</a>).  </p> <p>In FL, anthracycline‐based regimens are the most frequently employed first‐line treatment in the US, and are considerably utilized even in early‐stage disease (<a href="./references#CD008909-bbs2-0061" title="FriedbergJW , TaylorMD , CerhanJR , FlowersCR , DillonH , FarberCM , et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. Journal of Clinical Oncology2009;27(8):1202‐8. ">Friedberg 2009</a>), yet there is no proof of their superiority over regimens without anthracyclines. Even trials comparing single‐agent versus combination chemotherapy including anthracyclines have not consistently shown a benefit in response, relapse rate, or survival to combination therapy (<a href="./references#CD008909-bbs2-0069" title="ListerTA , CullenMH , BeardME , BrearleyRL , WhitehouseJM , WrigleyPF , et al. Comparison of combined and single‐agent chemotherapy in non‐Hodgkin's lymphoma of favourable histological type. BMJ1978;1(6112):533‐7. ">Lister 1978</a>). In some, a benefit was significant only in higher‐grade FL (<a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>) or in elderly patients (<a href="./references#CD008909-bbs2-0015" title="CoiffierB , Neidhardt‐BerardEM , TillyH , BelangerC , BouabdallahR , HaiounC , et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Annals of Oncology1999;10(10):1191‐7. ">Coiffier 1999</a>). Furthermore, it is undetermined whether the benefit may be attributed to anthracyclines, other drugs, or the combination in itself. </p> <p>In a retrospective study, 633 FL patients treated with anthracycline‐containing regimens (ACR) were compared to 128 comparable patients treated with combination chemotherapy not containing anthracyclines. The former group had better complete remission, five‐year OS, and failure‐free survival (FFS) (<a href="./references#CD008909-bbs2-0081" title="RigacciL , FedericoM , MartelliM , ZinzaniPL , CavannaL , BellesiG , et al. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leukemia &amp; Lymphoma2003;44(11):1911‐7. ">Rigacci 2003</a>). This stands in contrast to previous survival data of patients with low‐grade lymphoma entered into Southwest Oncology Group (SWOG) lymphoma trials, where doxorubicin‐containing treatment did not prolong the median OS, in comparison to less aggressive programs (<a href="./references#CD008909-bbs2-0058" title="DanaBW , DahlbergS , NathwaniBN , ChaseE , ColtmanC , MillerTP , et al. Long‐term follow‐up of patients with low‐grade malignant lymphomas treated with doxorubicin‐based chemotherapy or chemoimmunotherapy. Journal of Clinical Oncology1993;11(4):644‐51. ">Dana 1993</a>). Most other data come from indirect comparisons, comparing treatment arms from different trials (<a href="./references#CD008909-bbs2-0053" title="BrandtL , KimbyE , NygrenP , GlimeliusB . A systematic overview of chemotherapy effects in indolent non‐Hodgkin's lymphoma. Acta Oncologica2001;40(2‐3):213‐23. ">Brandt 2001</a>; <a href="./references#CD008909-bbs2-0051" title="BendandiM . Aiming at a curative strategy for follicular lymphoma. CA: A Cancer Journal for Clinicians2008;58(5):305‐17. ">Bendandi 2008</a>; <a href="./references#CD008909-bbs2-0089" title="TillyH , ZelenetzA . Treatment of follicular lymphoma: current status. Leukemia &amp; Lymphoma2008;49 Suppl 1:7‐17. ">Tilly 2008</a>; <a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>; <a href="./references#CD008909-bbs2-0084" title="SiddharthaG , VijayP . R‐CHOP versus R‐CVP in the treatment of follicular lymphoma: a meta‐analysis and critical appraisal of current literature. Journal of Hematology and Oncology2009;2:14. ">Siddhartha 2009</a>). An analysis of five consecutive studies at MD Anderson Cancer Center, involving advanced FL patients has shown improvement in OS and FFS over a 25‐year period (<a href="./references#CD008909-bbs2-0070" title="LiuQ , FayadL , CabanillasF , HagemeisterFB , AyersGD , HessM , et al. Improvement of overall and failure‐free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. Journal of Clinical Oncology2006;24(10):1582‐9. ">Liu 2006</a>). The fact that all protocols involved anthracyclines underscores the methodologic difficulty in comparing outcome rates in one trial with previous trials or historical cohorts, with versus without anthracyclines as is often done. Previous studies suggested that ACRs are advantageous specifically among patients with grade 3 FL (<a href="./references#CD008909-bbs2-0093" title="WendumD , SebbanC , GaulardP , CoiffierB , TillyH , CazalsD , et al. Follicular large‐cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B‐cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology1997;15(4):1654‐63. ">Wendum 1997</a>; <a href="./references#CD008909-bbs2-0055" title="ChauI , JonesR , CunninghamD , WotherspoonA , MaiseyN , NormanAR , et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front‐line therapy?. British Journal of Cancer2003;89(1):36‐42. ">Chau 2003</a>; <a href="./references#CD008909-bbs2-0062" title="GantiAK , WeisenburgerDD , SmithLM , HansCP , BociekRG , BiermanPJ , et al. Patients with grade 3 follicular lymphoma have prolonged relapse‐free survival following anthracycline‐based chemotherapy: the Nebraska Lymphoma Study Group Experience. Annals of Oncology2006;17(6):920‐7. ">Ganti 2006</a>), and show a plateau in FFS following ACR (<a href="./references#CD008909-bbs2-0050" title="BartlettNL , RizeqM , DorfmanRF , HalpernJ , HorningSJ . Follicular large‐cell lymphoma: intermediate or low grade?. Journal of Clinical Oncology1994;12(7):1349‐57. ">Bartlett 1994</a>). As a result, the recommended treatment for patients with grade 3 FL (both 3a and 3b) is now R‐CHOP, even in early‐stage disease (<a href="./references#CD008909-bbs2-0054" title="BuskeC , GisselbrechtC , GribbenJ , LetaiT , McLaughlinP , WilsonW . Refining the treatment of follicular lymphoma. Leukemia &amp; Lymphoma2008;49 Suppl 1:18‐26. ">Buske 2008</a>). </p> </section> <section id="CD008909-sec-0019"> <h3 class="title" id="CD008909-sec-0019">Why it is important to do this review</h3> <p>FL is the most common indolent NHL, yet there is no standard guideline for its management. It has been considered an incurable progressive disease, but in recent years, implementation of combination therapy and treatment with rituximab have prolonged survival and decreased transformation rate. ACRs are of the most prevalent first‐line therapies, especially in advanced disease, but also in limited or relapsed cases. However, there is no proof that they are superior to other, non‐ACRs, or even single‐agent therapy. Observational studies show conflicting results and other data are based on indirect comparisons that are not reliable. However, the optimal design for assessment of interventions is randomized controlled trials (RCTs). Anthracycline use is often limited to younger patients with more advanced or high‐grade disease, owing to concern of their adverse effects, especially cardiotoxicity, although it may be diminished in face of preventive strategies (<a href="./references#CD008909-bbs2-0090" title="vanDalenEC , van derPalHJ , CaronHN , KremerLCM . Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD005008.pub3] ">van Dalen 2009</a>). </p> <p>In this systematic review we assessed the evidence on the role of anthracyclines in the treatment of FL. This question is still important in the rituximab era, since the preferred combination chemotherapy used with it has not been elucidated. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008909-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008909-sec-0020"></div> <p>To compare the efficacy of ACRs to other chemotherapy regimens, in the treatment of FL. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008909-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008909-sec-0021"></div> <section id="CD008909-sec-0022"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008909-sec-0023"> <h4 class="title">Types of studies</h4> <p>We considered any published or unpublished RCT eligible for inclusion in this review, without language restriction. </p> </section> <section id="CD008909-sec-0024"> <h4 class="title">Types of participants</h4> <p>We included adult patients over 18 years of age, with a histologically confirmed diagnosis of FL, without gender or ethnicity restriction. If the trial had recruited patients with FL in addition to patients with other types of lymphoma, we included the study and extracted data for patients with FL separately. Where data were not provided separately for FL, we included the study and reported the number of patients with FL; we analyzed data only for studies with over 75% FL patients. We excluded studies that did not specify the number of FL patients enrolled. </p> <p>We considered all stages and grades of FL. Classification systems for FL varied between trials, as they were conducted at different times. Considering the different classification systems, we unified various nomenclatures in the following manner: </p> <p> <ul id="CD008909-list-0001"> <li> <p>grade 1 equivalent to follicular small cell lymphoma or CB/CC follicular or nodular lymphocytic poorly differentiated; </p> </li> <li> <p>grade 2 equivalent to mixed small and large cell FL or CB/CC follicular and diffuse or nodular mixed; </p> </li> <li> <p>grade 3 equivalent to large cell FL or CB/CC diffuse or nodular histiocytic. No equivalents to grade 3a and 3b in previous classifications. </p> </li> </ul> </p> <p>We included both trials assessing treatment‐naive patients and previously treated patients (with or without relapse). </p> </section> <section id="CD008909-sec-0025"> <h4 class="title">Types of interventions</h4> <p>The main intervention was an ACR compared to a non‐ACR, including any chemotherapy or immunochemotherapy. </p> <p>We defined the interventions as follows:</p> <p> <ul id="CD008909-list-0002"> <li> <p>intervention: ACR, regardless of additional agents, with or without radiotherapy;</p> </li> <li> <p>control: non‐ACR, as a single agent or multiple agents, regardless of dose.</p> </li> </ul> </p> <p>Anthracyclines considered in this review included doxorubicin (adriamycin), daunorubicin, idarubicin, epirubicin, mitoxantrone, and pixantrone. We included trials involving rituximab, interferon, or other novel chemoimmunotherapy only if the same chemotherapy regimen was administered in both arms. We excluded trials in which the control arm included one of the following: watchful waiting, radiotherapy alone, high‐dose chemotherapy with SCT. </p> <p>We separated trials according to the similarity of chemotherapeutic regimens, other than anthracyclines, between study arms. Trials with the same chemotherapy, where the main difference was the addition of an anthracycline, were summed together. Studies with different chemotherapies were described narratively. </p> </section> <section id="CD008909-sec-0026"> <h4 class="title">Types of outcome measures</h4> <p>We based the outcomes of this review on the revised response criteria for malignant lymphoma published in 2007 (<a href="./references#CD008909-bbs2-0057" title="ChesonBD , PfistnerB , JuweidME , GascoyneRD , SpechtL , HorningSJ , et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology2007;25(5):579‐86. ">Cheson 2007</a>). Given that some studies were conducted before these guidelines and that data were reported heterogeneously, we allowed for deviations from these definitions and documented the study definitions. </p> <section id="CD008909-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008909-list-0003"> <li> <p>OS, defined as the time from entry to study until death of any cause (<a href="./references#CD008909-bbs2-0057" title="ChesonBD , PfistnerB , JuweidME , GascoyneRD , SpechtL , HorningSJ , et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology2007;25(5):579‐86. ">Cheson 2007</a>) and assessed among all patients. In addition we assessed all‐cause mortality at three, five and 10 years. </p> </li> </ul> </p> </section> <section id="CD008909-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008909-list-0004"> <li> <p>PFS: defined as the time from entry into the study until lymphoma progression (including relapse) or death of any cause (<a href="./references#CD008909-bbs2-0057" title="ChesonBD , PfistnerB , JuweidME , GascoyneRD , SpechtL , HorningSJ , et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology2007;25(5):579‐86. ">Cheson 2007</a>). This outcome was analyzed for all patients. We accepted other outcome definitions (e.g. excluding non‐lymphoma‐related deaths) as long as all patients were accounted for. We also tried to extract the number of patients with progression (progression, relapse, or death from any cause) at three and five years out of all patients. </p> </li> <li> <p>CR: we accepted CR definitions as defined in study. In this category we included both documented and uncertain CR (CRu). </p> </li> <li> <p>Overall response rate (ORR), defined as CR + CRu + PR, as defined in study.</p> </li> <li> <p>RD: defined from the time when criteria for response (i.e. CR or PR) were met until the first documentation of relapse or progression (<a href="./references#CD008909-bbs2-0057" title="ChesonBD , PfistnerB , JuweidME , GascoyneRD , SpechtL , HorningSJ , et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology2007;25(5):579‐86. ">Cheson 2007</a>). This outcome was analyzed for the subgroup of patients achieving remission. We accepted other outcome definitions counting the subgroup of patients achieving remission and defining events as progression, relapse, need for treatment, or death (e.g. relapse‐free survival (RFS), event‐free interval). </p> </li> <li> <p>Relapse: number of patients with relapse out of those achieving CR. We extracted preferentially relapse at five years, but accepted other time points and documented these. </p> </li> <li> <p>Disease control: a general measure including various outcome measures reported in trials (i.e. PFS, RFS, event‐free survival, time to treatment failure, time to progression, or RD). These measures were often ill‐defined, and were not necessarily compatible with common guidelines (<a href="./references#CD008909-bbs2-0056" title="ChesonBD , HorningSJ , CoiffierB , ShippMA , FisherRI , ConnorsJM , et al. Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology1999;17(4):1244. ">Cheson 1999</a>; <a href="./references#CD008909-bbs2-0057" title="ChesonBD , PfistnerB , JuweidME , GascoyneRD , SpechtL , HorningSJ , et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology2007;25(5):579‐86. ">Cheson 2007</a>). The outcomes and their definitions are specified in the <a href="./references#CD008909-sec-0096" title="">Characteristics of included studies</a> table. </p> </li> <li> <p>Quality of life (QoL) assessed using validated questionnaires.</p> </li> <li> <p>Adverse events which were defined as follows:</p> <ul id="CD008909-list-0005"> <li> <p>cardiotoxicity ‐ clinical: defined on the basis of symptoms failure, confirmed by an abnormal diagnostic test; subclinical: defined as either histological abnormalities according to the Billingham score (<a href="./references#CD008909-bbs2-0052" title="BillinghamME , MasonJW , BristowMR , DanielsJR . Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatments Reports1978;62(6):865‐72. ">Billingham 1978</a>) on myocardial biopsy; or abnormalities in cardiac function measured by echocardiography or radionuclide ventriculography; </p> </li> <li> <p>myelosuppression defined as number of patients developing grade III/IV neutropenia (<a href="./references#CD008909-bbs2-0072" title="MillerAB , HoogstratenB , StaquetM , WinklerA . Reporting results of cancer treatment. Cancer1981;47(1):207‐14. ">Miller 1981</a>); </p> </li> <li> <p>infections, as defined in study;</p> </li> <li> <p>alopecia (<a href="./references#CD008909-bbs2-0072" title="MillerAB , HoogstratenB , StaquetM , WinklerA . Reporting results of cancer treatment. Cancer1981;47(1):207‐14. ">Miller 1981</a>); </p> </li> <li> <p>stomatitis (<a href="./references#CD008909-bbs2-0072" title="MillerAB , HoogstratenB , StaquetM , WinklerA . Reporting results of cancer treatment. Cancer1981;47(1):207‐14. ">Miller 1981</a>). </p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD008909-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted a comprehensive search with the purpose of identifying all eligible trials regardless of language, year of publication, or status of publication (published in peer review journal, conference proceeding, thesis, or unpublished). </p> <section id="CD008909-sec-0030"> <h4 class="title">Electronic searches</h4> <p>We searched the electronic databases of Cochrane Central Register of Controlled Trials (CENTRAL, published in <i>The Cochrane Library</i> 2013, Issue 3) and MEDLINE (January 1966 to April 2013). We have provided the different search strategies in <a href="./appendices#CD008909-sec-0087">Appendix 1</a> and <a href="./appendices#CD008909-sec-0088">Appendix 2</a>. We also searched the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) for ongoing or unpublished trials. </p> </section> <section id="CD008909-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We searched conference proceedings available from 2004 to 2012 of the following: the American Society of Hematology (ASH), European Hematology Association (EHA), and American Society of Clinical Oncology (ASCO). We scanned references of all included trials. </p> </section> </section> <section id="CD008909-sec-0032"> <h3 class="title" id="CD008909-sec-0032">Data collection and analysis</h3> <section id="CD008909-sec-0033"> <h4 class="title">Selection of studies</h4> <p>One review author (Gilad Itchaki (GI)) scanned the results of the search. Two review authors (GI, Mical Paul (MP)) independently applied inclusion and exclusion criteria for possibly relevant studies. </p> </section> <section id="CD008909-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted the data from included trials into an electronic table (GI, MP). We extracted the following data. </p> <section id="CD008909-sec-0035"> <h5 class="title">Trial characteristics</h5> <p> <ul id="CD008909-list-0006"> <li> <p>Trial design</p> </li> <li> <p>Setting and dates</p> </li> <li> <p>Total duration of study</p> </li> <li> <p>Duration of study follow‐up</p> </li> <li> <p>Exclusion criteria</p> </li> <li> <p>Statistical methods</p> </li> <li> <p>Publication status</p> </li> <li> <p>Funding</p> </li> <li> <p>Ethical committee approval and informed consent</p> </li> </ul> </p> </section> <section id="CD008909-sec-0036"> <h5 class="title">Risk of bias</h5> <p> <ul id="CD008909-list-0007"> <li> <p>We extracted data to assess the risk of bias, as specific below</p> </li> </ul> </p> </section> <section id="CD008909-sec-0037"> <h5 class="title">Patient characteristics</h5> <p> <ul id="CD008909-list-0008"> <li> <p>Mean age and sex</p> </li> <li> <p>Age over 60 years</p> </li> <li> <p>Histologic confirmation of FL</p> </li> <li> <p>Grade and stage (including B‐symptoms and bulky disease)</p> </li> <li> <p>Bone marrow involvement</p> </li> <li> <p>IPI or FLIPI score</p> </li> <li> <p>Indication for initiation of therapy</p> </li> <li> <p>Performance status (Eastern Cooperative Oncology Group (ECOG), Karnofsky)</p> </li> <li> <p>Time from diagnosis to first treatment</p> </li> <li> <p>Previous treatment</p> </li> <li> <p>Other medical conditions, specifically: cardiac, hepatic, or renal dysfunction</p> </li> <li> <p>Fulfillment of inclusion and exclusion criteria</p> </li> </ul> </p> </section> <section id="CD008909-sec-0038"> <h5 class="title">Interventions</h5> <p> <ul id="CD008909-list-0009"> <li> <p>Setting</p> </li> <li> <p>Type of chemotherapy, dose, number of cycles, possibility of dose reduction, addition of immunotherapy (type and dose) or radiation </p> </li> <li> <p>Cumulative anthracycline dose, peak dose, infusion duration</p> </li> <li> <p>Administration and timing of granulocyte‐colony stimulating factor (G‐CSF)</p> </li> <li> <p>Compliance</p> </li> <li> <p>Cross‐over and rate of completion</p> </li> </ul> </p> </section> <section id="CD008909-sec-0039"> <h5 class="title">Outcomes</h5> <p> <ul id="CD008909-list-0010"> <li> <p>As defined above. We documented and reported the definitions of time‐to‐event outcomes (including the population assessed, event definition, and whether all‐cause or disease‐related deaths were included in the outcome). </p> </li> </ul> </p> </section> </section> <section id="CD008909-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias in included studies and extracted the data into the electronic table. We used a domain‐based evaluation as recommended by the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008909-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Review authors were not blinded to trial authors, its publication status, or other study characteristics. We assigned each domain a low or high risk of bias, using the definitions provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008909-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). When there was insufficient information about the process, we assigned the domain an unclear risk of bias. We assessed the following domains for this review: </p> <p> <ul id="CD008909-list-0011"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants, personnel, and outcome assessors;</p> </li> <li> <p>incomplete outcome data: we assessed the number of exclusions and attrition for the primary outcomes and defined a priori high risk of bias when the number of randomized patients that were not included in outcome assessed was 30%; </p> </li> <li> <p>selective outcome reporting: we assessed this domain if the trial's protocol was available and predefined outcomes could be compared to those reported. In all other cases we have classified the domain as unclear, unless there was a discrepancy between the outcome results reported in the publication and those specified in its methods section (where an assignment of inadequate was be given); </p> </li> <li> <p>early stopping of the trial.</p> </li> </ul> </p> </section> <section id="CD008909-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data (deaths, CR, adverse events) we extracted the number of patients with events and number of patients assessed, and compared study groups using risk ratios (RRs). For survival data we extracted the summary effect measures as reported in the primary study, preferably hazard ratios (HRs) with 95% confidence intervals (CIs). If HRs were not reported, we tried to calculate them from the values reported on survival curves. We used the number of patients and events per group and P value to calculate the HR with 95% CIs, and the observed‐expected with variance (the latter was used in the meta‐analysis). When a P value was not reported, we manually estimated the percentage of events for several time points on the Kaplan Meier curve (at least three) and calculated the same values from these data. This was done using the excel spreadsheet developed by Sydes and Tierney (<a href="./references#CD008909-bbs2-0088" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>), which is based on the methods described in <a href="./references#CD008909-bbs2-0079" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a> and <a href="./references#CD008909-bbs2-0094" title="WilliamsonP , Tudur SmithC , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21:3337‐51. ">Williamson 2002</a>. </p> </section> <section id="CD008909-sec-0042"> <h4 class="title">Dealing with missing data</h4> <p>We tried to complement missing data regarding review‐defined outcomes and risk of bias assessment by correspondence with trial authors. None of the authors replied or could complete missing data. </p> <p>We have analyzed outcomes with missing data for some patients using available data only, since we were not able to impute missing values for time to event outcomes. </p> </section> <section id="CD008909-sec-0043"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity in each meta‐analysis using a Chi<sup>2</sup> test of heterogeneity and the I<sup>2</sup> statistic of inconsistency. Given the small number of studies in each of the analyses, we based the heterogeneity assessment mainly on the I<sup>2</sup> statistic where a value greater than 50% represents substantial heterogeneity. We interpreted the importance of the observed I<sup>2</sup> value by looking at the magnitude and the direction of effects. </p> </section> <section id="CD008909-sec-0044"> <h4 class="title">Assessment of reporting biases</h4> <p>In analyses that include at least 10 trials we planned to draw funnel plots of effect estimates against study precision, and inspect asymmetry visually and indicate publication bias or other small study effects (<a href="./references#CD008909-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). However, all analyses were of five trials or less. </p> </section> <section id="CD008909-sec-0045"> <h4 class="title">Data synthesis</h4> <p>We pooled RRs with 95% CIs using the fixed‐effect model. We recalculated all analyses using the random‐effects model, and reported significant discrepancies between the models. HRs were pooled according to Peto's method. Analyses were done in RevMan 5 (<a href="./references#CD008909-bbs2-0080" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5,2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> </section> <section id="CD008909-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>As detailed above, we conducted a separate analysis for studies assessing directly the efficacy of anthracyclines by comparing the same chemotherapy regimens with or without the addition of an anthracycline. We set to investigate heterogeneity in each analysis based on the following preplanned subgroup analyses: </p> <p> <ul id="CD008909-list-0012"> <li> <p>FL grade 3;</p> </li> <li> <p>age over 60 years;</p> </li> <li> <p>first‐line versus relapse or refractory;</p> </li> <li> <p>regimens with or without monoclonal antibodies;</p> </li> <li> <p>different anthracyclines.</p> </li> </ul> </p> <p>However, the paucity of trials and lack of data in included studies allowed for subgroup analyses of the last count alone. </p> </section> <section id="CD008909-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p> <ul id="CD008909-list-0013"> <li> <p>Allocation concealment (see above), which has been shown to affect subjective outcomes most strongly (<a href="./references#CD008909-bbs2-0095" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). We planned to assess the effect of blinding, but all trials were open‐labelled. </p> </li> <li> <p>Trials that encompassed a second randomization.</p> </li> <li> <p>Publication status: published in a peer‐reviewed journal.</p> </li> </ul> </p> <p>Given the paucity of included trials, we were able to fulfil only the first two counts, and did not undertake any further sensitivity analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008909-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008909-sec-0048"></div> <section id="CD008909-sec-0049"> <h3 class="title">Description of studies</h3> <section id="CD008909-sec-0050"> <h4 class="title">Results of the search</h4> <p>See <a href="./references#CD008909-sec-0096" title="">Characteristics of included studies</a>; <a href="./references#CD008909-sec-0097" title="">Characteristics of excluded studies</a>; ; and <a href="./references#CD008909-sec-0098" title="">Characteristics of ongoing studies</a> tables. </p> <p>A total of 1324 potentially relevant titles and abstracts were identified and screened for retrieval. Forty‐six were evaluated in more detail. Of these, 38 were excluded. Additional five ongoing trials were identified, of which two were terminated, two are ongoing and one was published in abstract form and excluded, since no randomization was done between ACR and non‐ACR (<a href="./references#CD008909-bbs2-0017" title="FlinnEW , Van derJagtRH , KahlBS , WoodP , HawkinsTE , MacDonaldD , et al. An open‐label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R‐CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) in first‐line treatment of patients with advanced indolent non‐Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL): The BRIGHT Study. Blood (ASH Annual Meeting Abstracts)2012;120(21):Abstract No 902. ">Flinn 2012</a>). See <a href="#CD008909-fig-0001">Figure 1</a> for a flow diagram of the search. </p> <div class="figure" id="CD008909-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008909-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008909-sec-0051"> <h4 class="title">Included studies</h4> <p>Eight RCTs were included in the systematic review, involving a total of 2636 randomized adult patients. Trials were conducted between 1974 and 2011, yet most were published in the 1980s and 1990s. Six studies recruited patients in Europe and two (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>) in the US. Six trials were conducted as part of a study group (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0003" title="KimbyE , BjorkholmM , GahrtonG , GlimeliusB , HagbergH , JohanssonB , et al. Chlorambucil/prednisone vs. CHOP in symptomatic low‐grade non‐Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology1994;5 Suppl 2:67‐71. ">Kimby 1994</a>; <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>; <a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>), and two were not (<a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>). All were multicenter trials. Time of follow‐up varied between three years and 18 years. Most trials reported outcomes at three to five years, while two trials (<a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>) also reported outcomes at 10 years or more. </p> <section id="CD008909-sec-0052"> <h5 class="title">Type of participants</h5> <p>All trials involved patients with low‐grade NHL. Jones et al (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>) also included patients with high‐grade lymphoma, yet stratification and analysis was separate for patients with FL. All trials included patients with initial, untreated indolent NHL. In these trials, no prior chemotherapy was allowed. In three trials (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>) prior radiotherapy to bulky regions was allowed, but was given in very few patients (not reported in <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>). </p> <p>Classification systems were not identical: three trials used REAL/WHO classification; three used Kiel classification initially, but two of those eventually reported results according to REAL classification; one used Working Formulation; and one used Rappaport classification. </p> <p>In all studies recruitment was based on the pathologic diagnosis of the primary institution, yet central pathology reclassification was performed. Analysis was done according to initial classification, with subgroup analysis according to central pathology, except for one trial (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>) where changes in classification were frequent and analysis was based on central pathology alone. </p> <p>Four trials ( <a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0003" title="KimbyE , BjorkholmM , GahrtonG , GlimeliusB , HagbergH , JohanssonB , et al. Chlorambucil/prednisone vs. CHOP in symptomatic low‐grade non‐Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology1994;5 Suppl 2:67‐71. ">Kimby 1994</a>; <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>; <a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>) included only patients with advanced lymphoma (stage III/IV according to the Ann Arbor classification); three trials (<a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>) included patients with stage II to IV NHL; and one trial (<a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>) considered all patients eligible for treatment, yet only one patient with stage I disease was included. Of reported data, 96% of patients were stage III or IV. </p> <p>All trials reported histology consistent with FL. They included 1520 evaluated patients with histologically confirmed FL. However, only two trials (<a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>) were designed specifically for FL patients. Other common indolent lymphomas included in studies were chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and immunocytoma and mantle cell lymphoma (MCL). Grades of FL were reported in most trials, as specified in Additional <a href="#CD008909-tbl-0002">Table 1</a>. Most randomized FL patients were grade 1 or 2. </p> <div class="table" id="CD008909-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies included in meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomized</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analyzed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FL analyzed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FL grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Data specific for FL</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Federico 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>504 (333)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2, 3a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For all outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Jones 1983</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226 (146)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2, 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For all outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lepage 1990</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Taylor 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Zinzani 2000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indolent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kimby 1994</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Peterson 2003</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For all outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unterhalt 1996</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2636</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2189</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1520</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>* number of FL patients analyzed in 2 (of 3) arms compared<br/> FL: follicular lymphoma </p> </div> </div> <p>Common exclusion criteria were: severe cytopenias; significant kidney and liver disease; high ECOG score; cardiac failure contraindicating use of anthracyclines; and, where appropriate, any pulmonary dysfunction contraindicating use of bleomycin. </p> <p>All patients were given first‐line treatment. Usual indications for treatment, when reported, were symptomatic, progressive or bulky disease, or cytopenia. In one trial (<a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>) treatment was started within 100 days of diagnosis, regardless of symptoms. FLIPI/IPI score was reported in three trials (<a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>). In the <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a> and <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a> trials up to 37% of patients had a high FLIPI score. In <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>, 27% of patients also had a high FLIPI2 score. </p> </section> <section id="CD008909-sec-0053"> <h5 class="title">Study design</h5> <p>In four studies (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>) two consecutive randomization processes were performed (patients were randomized to type of induction therapy and then randomized again to maintenance therapy or observation). Our analyses refer to the first randomization. </p> <p>Two studies had a triple‐arm design. <a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a> compared CHOP‐Bleo (cyclophosphamide, doxorubicin, vincristine, prednisone, bleomycin) versus CVP‐Bleo (cyclophosphamide, vincristine, prednisone, bleomycin) versus CHOP‐BCG (cyclophosphamide, doxorubicin, vincristine, prednisone, Bacillus Calmette Guerin). Since BCG was given also as part of induction therapy, and might be considered an immunotherapy, we did not extract data from this arm. <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a> compared R‐CVP versus R‐CHOP versus R‐FM. We extracted data only for the first comparison, according to protocol. </p> </section> <section id="CD008909-sec-0054"> <h5 class="title">Intervention</h5> <p>Five studies (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>) assessed the same chemotherapeutic regimen between study arms, yet only three trials reported OS data for FL patients specifically. </p> <p>Importantly, three trials with 'same chemotherapies' were not exactly identical. <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a> compared fludarabine with fludarabine‐idarubicin combination, yet fludarabine was given for five days in the control arm and only three days in the experimental arm. In <a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a> (CVP‐B versus CHOP‐B), the administration of cyclophosphamide varied by route, rate, and total dose between study arms, and there were also minor differences in bleomycin dose and frequency of cycles. In <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a> (R‐CVP versus R‐CHOP), eight versus six cycles were given between non‐ACR and ACR arms, but the number of rituximab cycles was identical. Since regimens were basically similar, and higher doses were administered in the control arms, we have decided to pool results of these trials as 'same chemotherapy'. </p> <p>Three studies (<a href="./references#CD008909-bbs2-0003" title="KimbyE , BjorkholmM , GahrtonG , GlimeliusB , HagbergH , JohanssonB , et al. Chlorambucil/prednisone vs. CHOP in symptomatic low‐grade non‐Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology1994;5 Suppl 2:67‐71. ">Kimby 1994</a>; <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>; <a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>) compared different regimens in the ACR and non‐ACR arms. For baseline characteristics of interventions see Additional <a href="#CD008909-tbl-0003">Table 2</a>. For a detailed comparison of therapeutic regimens see Additional <a href="#CD008909-tbl-0004">Table 3</a>. </p> <div class="table" id="CD008909-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Publication status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Same/different intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Anthracycline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Experimental arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Federico 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R‐CVP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R‐CHOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Jones 1983</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CVP‐B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHOP‐B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lepage 1990</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Taylor 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Idarubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ChD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ChID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Zinzani 2000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Idarubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kimby 1994</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ch‐D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Peterson 2003</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unterhalt 1996</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mitoxantrone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CVP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PmM</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* trials with higher non‐anthracycline dose in control‐arm</p> </div> </div> <div class="table" id="CD008909-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Detailed therapeutic regimens in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Experimental arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Federico 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 rituximab 375 mg/m<sup>2</sup>, d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 40 mg/m<sup>2</sup> PO, 8 cycles, every 21 d </p> <p><i>[Note: more treatment cycles]</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 rituximab 375 mg/m<sup>2</sup>, d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 doxorubicin 50 mg/m<sup>2</sup> IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 100 mg/d PO 6 cycles, every 21 d. Added 2 cycles of rituximab every 21 d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Jones 1983</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐14 cyclophosphamide 125 mg/m<sup>2</sup> PO, d 1, 8 vincristine 1.4 mg/m<sup>2</sup> IV (max 2 mg/dose), d 1‐5 prednisone 100 mg/d PO, d 1, 8 bleomycin 4 mg/m<sup>2</sup> IV. 8 cycles, every 21 d </p> <p><i>[Note: different route of administration for cyclophosphamide; total doses differ for all drugs; cycles are more frequent]</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 doxorubicin 50 mg/m<sup>2</sup> IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 100 mg/d PO, d 1 bleomycin 4 mg/m<sup>2</sup> IV. 8 cycles, every 28 d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lepage 1990</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1, 8 cyclophosphamide 400 mg/m<sup>2</sup> IV, d 1, 8 vincristine 1.4 mg/m<sup>2</sup> , d 1, 14 procarbazine 80 mg/m<sup>2</sup> PO, d 1‐5 prednisone 60 mg/m<sup>2</sup> PO. 6 cycles, every 28 d </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>same + d 1, 8 doxorubicin 20 mg/m<sup>2</sup> IV </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Taylor 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐3 chlorambucil 20 mg/m<sup>2</sup>/d, d 1‐5 dexamethasone 4 mg bd. 6 cycles, every 21 d </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>same + d 1‐3 idarubicin 10 mg/m<sup>2</sup>/d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Zinzani 2000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐5 fludarabine 25 mg/m<sup>2</sup>/d IV. 6 cycles, every 28 d<br/> <i>[Note: total fludarabine dose is higher by 66%]</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐3 fludarabine 25 mg/m<sup>2</sup>/d IV, d 1‐3, d 1 idarubicin 12 mg/m<sup>2</sup> 6 cycles, every 28 d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kimby 1994</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 chlorambucil 0.4 mg/kg PO, d 1‐3 prednisone 75 mg PO every 14 d, for 4‐8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 doxorubicin 50 mg/m<sup>2</sup> IV, d 1 vincristine 2 mg/m<sup>2</sup> IV, d 1‐5 prednisone 50 mg/m<sup>2</sup> PO 4‐8 cycles every 28 d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Peterson 2003</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 doxorubicin 50 mg/m<sup>2</sup> IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 60 mg/m<sup>2</sup> PO, d 1 bleomycin 10 u/m<sup>2</sup> IM every 21 d until complete response and then every 28 d up to 2 years, bleomycin up to 6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 mg/m<sup>2</sup>/d PO until 2 years from maximal response </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unterhalt 1996</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐5 cyclophosphamide 400 mg/m<sup>2</sup>/d IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 100 mg/m<sup>2</sup>/d PO 4‐6 induction cycles every 21 d </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐5 prednimustine 100 mg/m<sup>2</sup>/d PO, d 1‐2 mitoxantrone 8 mg/m<sup>2</sup>/d IV. 4‐6 induction cycles every 28 d </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>d: day; IM: intramuscular; IV: intravenous; PO: oral</p> </div> </div> <p>Different anthracyclines were used in the studies: five used doxorubicin (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0003" title="KimbyE , BjorkholmM , GahrtonG , GlimeliusB , HagbergH , JohanssonB , et al. Chlorambucil/prednisone vs. CHOP in symptomatic low‐grade non‐Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology1994;5 Suppl 2:67‐71. ">Kimby 1994</a>; <a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>); two used idarubicin (<a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>); and one used mitoxantrone (<a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>). Rituximab was used only in <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>. </p> </section> <section id="CD008909-sec-0055"> <h5 class="title">Outcome assessment</h5> <p>All but one trial (<a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>) assessed OS, although not necessarily as the primary outcome. However, <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a> did not eventually report OS data and <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a> did not report OS separately in FL patients. Finally, only three trials with similar chemotherapeutic regimens were analyzed for survival (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>). </p> <p>All trials assessed response rate, although definitions were not uniform across trials. Outcomes regarding disease control varied considerably across trials, and commonly were not compatible with the subsequently published criteria for reporting outcomes from clinical trials (<a href="./references#CD008909-bbs2-0056" title="ChesonBD , HorningSJ , CoiffierB , ShippMA , FisherRI , ConnorsJM , et al. Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology1999;17(4):1244. ">Cheson 1999</a>; <a href="./references#CD008909-bbs2-0057" title="ChesonBD , PfistnerB , JuweidME , GascoyneRD , SpechtL , HorningSJ , et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology2007;25(5):579‐86. ">Cheson 2007</a>). The outcomes and their definitions are specified in the <a href="./references#CD008909-sec-0096" title="">Characteristics of included studies</a> table. </p> </section> </section> <section id="CD008909-sec-0056"> <h4 class="title">Excluded studies</h4> <p>Thirty‐nine trials were excluded (including one ongoing trial, <a href="./references#CD008909-bbs2-0017" title="FlinnEW , Van derJagtRH , KahlBS , WoodP , HawkinsTE , MacDonaldD , et al. An open‐label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R‐CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) in first‐line treatment of patients with advanced indolent non‐Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL): The BRIGHT Study. Blood (ASH Annual Meeting Abstracts)2012;120(21):Abstract No 902. ">Flinn 2012</a>). Reasons for exclusion were as follows: eight were non‐randomized; five did not include patients with FL; four did not include anthracyclines in study arms and two included anthracyclines in both study arms (one study with multiple combinations); three trials compared irradiation to ACR; one trial had immunotherapy (interferon) only in one study arm; one involved different chemotherapeutic regimens in conjunction with immunotherapy (rituximab); two did not randomize between ACR and non‐ACR arms; one was a cross‐over trial; one article emphasized comparison of different diseases rather than therapeutic arms; two were reviews; in two relevant outcome data could not be retrieved; and five were double publications, that did not add information to the main articles. Three trials reported results for indolent NHL patients, but did not specify the number of FL patients included. <a href="./references#CD008909-bbs2-0010" title="Al‐IsmailSA , WhittakerJA , GoughJ . Combination chemotherapy including epirubicin for the management of non‐Hodgkin's lymphoma. European Journal of Cancer &amp; Clinical Oncology1987;23(9):1379‐84. ">Al‐Ismail 1987</a> randomized 47 low grade lymphoma patients between CVP and epirubicin, vincristine, prednisolone (EPV) regimen. There was no difference in response rates, response duration or OS. <a href="./references#CD008909-bbs2-0037" title="PrenticeAG , JohnsonSAN , HarperM , HewinsP , TyrrellCJ , CopplestoneJA , et al. A randomised, prospective trial of chlorambucil and prednisolone (CP) v mitozantrone, chlorambucil and prednisolone (MCP) in de novo, stage II or more advanced, low‐grade non‐Hodgkins lymphoma (LG‐NHL). British Journal of Haematology (Annual Meeting of the British Society for Haematology)1996;93 Suppl 1:74 Abstract No 286. ">Prentice 1996</a>, published only in abstract form, randomized 182 patients with low grade NHL, that were stage II or more, between chlorambucil‐prednisone combination and same therapy with mitoxantrone. The results indicated benefit for ACR, with a higher rate of CR (58% versus 44%, P = 0.02); longer disease‐free survival (2.98 years versus not reached); and longer OS (median of 3.31 years versus not reached). Lastly, <a href="./references#CD008909-bbs2-0043" title="SantoroA , VoglovaJ , GabrailN , CiuleanuT , LiberatiM , HancockBW , et al. Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non‐Hodgkin's lymphoma (NHL). Journal of Clinical Oncology (ASCO Annual Meeting Proceedings)2006;24 Suppl(18):Abstract No 7578. ">Santoro 2006</a>, also published in abstract form, compared rituximab as single agent with pixantrone and rituximab combination, in 38 relapsed and refractory indolent NHL patients. Response rates were higher in the immunochemotherapy combination, as was progression‐free survival, although data are missing from abstract, and we could not retrieve any further information from authors. </p> </section> </section> <section id="CD008909-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>All included studies were described as RCTs. Generation of randomization sequence was assessed as adequate for four trials, where it was done centrally (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0003" title="KimbyE , BjorkholmM , GahrtonG , GlimeliusB , HagbergH , JohanssonB , et al. Chlorambucil/prednisone vs. CHOP in symptomatic low‐grade non‐Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology1994;5 Suppl 2:67‐71. ">Kimby 1994</a>; <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>). The other studies did not describe the methods used for generation of randomization and hence were classified as unclear. Allocation concealment was assessed as adequate in five trials (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0003" title="KimbyE , BjorkholmM , GahrtonG , GlimeliusB , HagbergH , JohanssonB , et al. Chlorambucil/prednisone vs. CHOP in symptomatic low‐grade non‐Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology1994;5 Suppl 2:67‐71. ">Kimby 1994</a>; <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>) and not reported in the other trials. None of the trials were blinded (<a href="#CD008909-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD008909-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD008909-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>Two trials were stopped early. In <a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>, the control arm (CVP‐B) was stopped early when inferiority was suspected. Moreover, 652 patients were randomized in this trial, but only 497 were centrally reclassified and analyzed. <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a> enrolled 442 patients, 42 of whom were excluded owing to protocol violation and NHL subtypes not in concert with trial. However, after only 246 patients were analyzed, the authors' basic assumption of a 20% improvement in overall response could be rejected. Hence, analysis of remaining patients was abandoned, and it was not specified in two double publications (<a href="./references#CD008909-bbs2-0023" title="HiddemannW , UnterhaltM , KochP , NahlerM , HerrmannR . New aspects in the treatment of advanced low‐grade non‐Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only ‐ a preliminary update of the German Low‐Grade Lymphoma Study Group. Seminars in Hematology1994;31 Suppl 3(2):32‐5. ">Hiddemann 1994</a>; <a href="./references#CD008909-bbs2-0045" title="UnterhaltM , KochP , PfreundschuhM , MaschmeyerG , FreundM , ThielF , et al. Prednimustine, mitoxantrone (PMM) versus cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low grade non‐Hodgkin's lymphoma. Blood1994;84 Suppl 1:Abstract No 656. ">Unterhalt 1994</a>). </p> <p>Trials stated that analysis was done on an intention‐to‐treat (ITT) basis, but in most cases, the provided data could not fully support this statement. Drop‐out rate was less than 10% in all but one trial (<a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>). Incomplete outcome data could not be well assessed also for <a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a> where data were analyzed only for 497 patients with centrally reviewed pathologies, out of total of 636 eligible randomized patients. Thus, according to incomplete outcome data, six trials were considered as low risk for attrition bias and two as high risk. </p> <p>In <a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>, data were reported for 228 patients (six patients were excluded, three in each arm). Of those, a separate analysis was made for 189 patients with confirmed central pathology, in order to compare between grade 1 and grade 2 FL. In our analysis, we used data from the whole cohort, which is more elaborate and where outcomes were reported on an ITT basis. </p> <p>Selective outcome reporting could not be assessed since most trials were old and trial registry or protocol were unavailable. The outcomes reported were in accordance with those specified in the methods section of the final publication. </p> <p><a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a> reported a protocol violation that may have confounded results, as more patients in the experimental arm received radiotherapy, although they did not initially suffer from a bulky disease. They were included in the analysis on an ITT basis. </p> <p>All trials were published in peer‐reviewed journals, and all reported ethics committee approval and that informed consent was obtained from the patients. </p> <p>Three trials declared their funding resources, and were not supported by the pharmaceutical industry (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>). Five studies did not report funding resources (<a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0003" title="KimbyE , BjorkholmM , GahrtonG , GlimeliusB , HagbergH , JohanssonB , et al. Chlorambucil/prednisone vs. CHOP in symptomatic low‐grade non‐Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology1994;5 Suppl 2:67‐71. ">Kimby 1994</a>; <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a>; <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>). </p> </section> <section id="CD008909-sec-0058"> <h3 class="title" id="CD008909-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD008909-tbl-0001"><b>Summary of findings for the main comparison</b> ACR compared to non‐ACR for treatment of follicular lymphoma in adults</a> </p> <section id="CD008909-sec-0059"> <h4 class="title">Studies comparing same chemotherapy</h4> <p>Five of the eight trials included in this review administered the same chemotherapy (other than anthracyclines). The following sections report outcome measures of these trials alone, and when possible, sum their total effect. We analyzed data specifically for FL patients, or from trials with over 75% FL patients. Three of the trials used higher doses of non‐anthracycline therapies in the control arm. When possible, we examined the effect of those trials separately. In <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>, FL patients constituted only about a half of the cohort. Results were included in analysis, only for parameters reported separately for FL patients. </p> <p>The three trials that used different chemotherapies in study arms, will be described separately. Since the regimens differ considerably between trials, we did not sum their effect, but rather summarized them in a table. </p> <section id="CD008909-sec-0060"> <h5 class="title">Overall survival</h5> <p>OS data were analyzed for 464 patients included in three studies (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>). The pooled HR for OS was 0.99 (95% CI 0.77 to 1.29; <a href="#CD008909-fig-0003">Figure 3</a>), indicating that there was no advantage to ACR chemotherapy compared with other chemotherapy. There was no heterogeneity among trials (P = 0.37; I<sup>2</sup> = 0%). <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a> did not publish mortality data, as it was under‐powered to assess survival. We did not include <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a> in the analysis, since survival data were reported for the whole cohort, and not specifically for FL. However, adding it did not change the pooled results (HR 0.97; 95% CI 0.76 to 1.23, <a href="./references#CD008909-fig-0011" title="">Analysis 1.2</a>). </p> <div class="figure" id="CD008909-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.1 Overall survival." data-id="CD008909-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.1 Overall survival. </p> </div> </div> </div> </section> <section id="CD008909-sec-0061"> <h5 class="title">All‐cause mortality</h5> <p>There was no difference between ACR and non‐ACR chemotherapy for mortality at three years (RR 0.92; 95% CI 0.67 to 1.26; three trials; <a href="#CD008909-fig-0004">Figure 4</a>), and no heterogeneity among trials (P = 0.48; I<sup>2</sup> = 0%). We found similar results for five‐year mortality (RR 0.95; 95% CI 0.77 to 1.18; three trials; 539 patients; <a href="./references#CD008909-fig-0013" title="">Analysis 1.4</a>). Data regarding 10‐year all‐cause mortality were reported only in <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>, where there was no benefit to anthracyclines. </p> <div class="figure" id="CD008909-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.3 Mortality at 3 years." data-id="CD008909-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.3 Mortality at 3 years. </p> </div> </div> </div> </section> <section id="CD008909-sec-0062"> <h5 class="title">Response rate (CR and ORR)</h5> <p>All trials contributed to the analysis of CR, and all reported response data for FL patients separately. Use of ACR was not statistically significantly better than non‐ACR (RR 1.05; 95% CI 0.94 to 1.18; <a href="#CD008909-fig-0005">Figure 5</a>), yet there was moderate heterogeneity between trials (P = 0.12; I<sup>2</sup> = 46%). One trial, showing the opposite, contributed to the heterogeneity (<a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>). This discrepancy may arise from the higher dose of fludarabine in the control arm. Excluding <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a> from the analysis did not change results (RR 1.11; 95% CI 0.99 to 1.25; I<sup>2</sup> = 0%). Also, using the random‐effects model did not considerably change the analysis (RR 1.03; 95% CI 0.86 to 1.23). </p> <div class="figure" id="CD008909-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.5 Complete response." data-id="CD008909-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.5 Complete response. </p> </div> </div> </div> <p>ORR data were available in three trials (<a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>), analyzing 616 patients. The pooled RR was 1.06 (95% CI 1.00 to 1.12; I<sup>2</sup> = 12%; <a href="./references#CD008909-fig-0015" title="">Analysis 1.6</a>), with a probable effect for ACR, although not statistically significant. </p> </section> <section id="CD008909-sec-0063"> <h5 class="title">Disease control</h5> <p>Disease control measures were reported in four trials using same chemotherapy (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>). End points, as specified in studies, were: PFS, RFS, TTTF, and PFS, respectively (for outcomes definitions see <a href="./references#CD008909-sec-0096" title="">Characteristics of included studies</a> table). However, these measures were often ill‐defined, or were not necessarily compatible with common guidelines. <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>, for example, used PFS to describe remission duration (RD) in responding patients. </p> <p>With respect to disease control, ACRs were superior to non‐ACRs, with a pooled HR of 0.65 (95% CI 0.52 to 0.81; <a href="#CD008909-fig-0006">Figure 6</a>), with some heterogeneity (I<sup>2</sup> = 46%; P = 0.14) resulting only from differential benefit for ACR. </p> <div class="figure" id="CD008909-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.7 Disease control." data-id="CD008909-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.7 Disease control. </p> </div> </div> </div> <p>Disease control outcomes could be divided into two groups, according to time from which outcomes were counted: PFS, where outcomes were counted from randomization, and RD, which include only patients responding to treatment from end of therapy. ACRs retained their benefit for PFS (two studies; HR 0.65; 95% CI 0.50 to 0.84) and RD (two studies, HR 0.63; 95% CI 0.40 to 0.98), separately (<a href="#CD008909-fig-0006">Figure 6</a>). </p> </section> <section id="CD008909-sec-0064"> <h5 class="title">Progression or relapse</h5> <p>Progression or relapse was chosen as a complementary dichotomous measure of disease control, relevant in patients with FL. This outcome was assessed in four trials (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>), and could be extracted at three years in all trials. The pooled RR for previously untreated FL was 0.73 (95% CI 0.63 to 0.85; little heterogeneity I<sup>2</sup> = 7%; <a href="#CD008909-fig-0007">Figure 7</a>), indicating that therapy‐naive FL patients treated with ACR had a lower progression rate at three years. </p> <div class="figure" id="CD008909-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.8 Progression or relapse at 3 years." data-id="CD008909-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.8 Progression or relapse at 3 years. </p> </div> </div> </div> </section> <section id="CD008909-sec-0065"> <h5 class="title">Toxicity</h5> <section id="CD008909-sec-0066"> <h6 class="title">Neutropenia</h6> <p>Four trials reported neutropenia as a serious event, but only two (<a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>) were amenable for meta‐analysis, demonstrating a higher rate of grade 3‐4 neutropenia with ACR (RR 1.94; 95% CI 1.46 to 2.56; <a href="./references#CD008909-fig-0018" title="">Analysis 1.9</a>). <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a> (fludarabine‐idarubicin‐ versus fludarabine) reported equal distribution of neutropenia (toxicity over treatment cycles rather than absolute episodes). However, a higher dose of fludarabine was administered in the control arm. <a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a> gave a qualitative description of more neutropenia in ACR‐treated patients. </p> </section> <section id="CD008909-sec-0067"> <h6 class="title">Infection</h6> <p>The types of infection reported varied considerably between any infection, serious infection, and neutropenic fever. Three trials were included in a meta‐analysis considering the infection reported in the study (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>). The pooled RR of anthracyclines was 1.16 (95% CI 0.75 to 1.80; <a href="#CD008909-fig-0008">Figure 8</a>) with considerable heterogeneity (I<sup>2</sup> = 51%; P = 0.13). </p> <div class="figure" id="CD008909-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.10 Infection." data-id="CD008909-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.10 Infection. </p> </div> </div> </div> </section> <section id="CD008909-sec-0068"> <h6 class="title">Cardiotoxicity</h6> <p>Cardiotoxicity was reported in three trials that employed similar regimens. In <a href="./references#CD008909-bbs2-0026" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Superiority of adriamycin‐containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer1979;43(2):417‐25. ">Jones 1979</a>, 11 cardiac events were recorded in 472 patients receiving ACR (including patients from a third arm of CHOP‐BCG). <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a> had no cardiac events in both arms. <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a> reported one grade 3‐4 event in each study arm. </p> </section> </section> <section id="CD008909-sec-0069"> <h5 class="title">Quality of life</h5> <p>QoL was not assessed in the included trials. However, nausea and vomiting, diarrhea, and mucositis were reported more often with ACR. </p> </section> <section id="CD008909-sec-0070"> <h5 class="title">Sensitivity analysis</h5> <p>There was no evidence for OS benefit of anthracyclines in trials reporting adequate allocation concealment or in those with unclear allocation concealment (<a href="./references#CD008909-fig-0020" title="">Analysis 2.1</a>). ACR were superior to non‐ACR in terms of disease control, regardless of allocation concealment quality (HR 0.70; 95% CI 0.52 to 0.95 and HR 0.58; 95% CI 0.41 to 0.81, respectively; P = 0.38 for subgroup difference; <a href="./references#CD008909-fig-0021" title="">Analysis 2.2</a>). </p> <p>All studies were published as peer‐reviewed journal articles.</p> <p>As mentioned above, three studies proceeded to a second randomization (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>), and only these trials reported OS. Second randomization did not influence disease control (P value for subgroup difference was 0.26, <a href="./references#CD008909-fig-0022" title="">Analysis 3.1</a>). </p> </section> <section id="CD008909-sec-0071"> <h5 class="title">Subgroup analysis</h5> <p>There were not sufficient outcome data for subgroup analysis according to grade of FL or age of patients. Also, all patients included had first‐line therapy. Only <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a> had included monoclonal antibodies (rituximab) in study arms. Its results were consistent with those of the other studies. </p> <p>We undertook subgroup analysis of the different anthracyclines used. Regarding OS, trials employing the same chemotherapies used either doxorubicin (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0004" title="LepageE , SebbanC , GisselbrechtC , CoiffierB , HarousseauJL , BryonPA , et al. Treatment of low‐grade non‐Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology1990;8(1):31‐9. ">Lepage 1990</a>) or idarubicin (<a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>). There was no evidence of survival benefit to either type of anthracycline, as shown in <a href="./references#CD008909-fig-0023" title="">Analysis 4.1</a>. Disease control measures were reported in two trials employing doxorubicin (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>) and two trials using idarubicin (<a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>). The advantage of anthracyclines in disease control was preserved regardless of type of anthracycline used, as shown in <a href="#CD008909-fig-0009">Figure 9</a>. </p> <div class="figure" id="CD008909-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Comparison of different anthracyclines, outcome: 4.2 Disease control." data-id="CD008909-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Comparison of different anthracyclines, outcome: 4.2 Disease control. </p> </div> </div> </div> </section> </section> <section id="CD008909-sec-0072"> <h4 class="title">Studies comparing different chemotherapies</h4> <p>Three trials used different regimens between study arms, and among trials themselves, and therefore could not be summed together. </p> <p><a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a> compared CHOP‐B with continuous cyclophosphamide PO; <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a> compared prednimustine‐mitoxantrone with CVP regimen; and <a href="./references#CD008909-bbs2-0003" title="KimbyE , BjorkholmM , GahrtonG , GlimeliusB , HagbergH , JohanssonB , et al. Chlorambucil/prednisone vs. CHOP in symptomatic low‐grade non‐Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology1994;5 Suppl 2:67‐71. ">Kimby 1994</a> evaluated CHOP with chlorambucil‐dexamethasone, both given PO (<a href="./references#CD008909-sec-0096" title="">Characteristics of included studies</a>). </p> <p>The effects of interventions are summarized in Additional <a href="#CD008909-tbl-0005">Table 4</a>, and graphically in <a href="./references#CD008909-fig-0025" title="">Analysis 5.1</a>; <a href="./references#CD008909-fig-0026" title="">Analysis 5.2</a>; <a href="./references#CD008909-fig-0027" title="">Analysis 5.3</a>; and <a href="./references#CD008909-fig-0028" title="">Analysis 5.4</a>. Consistent with pooled results presented for trials comparing the same chemotherapy, there was no evidence of effect on survival, three‐, and five‐year mortality for the ACR arms. All trials showed a trend in favour of anthracyclines for disease control. Results for CR and OR were heterogeneous. </p> <div class="table" id="CD008909-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Outcome measures in trials with different chemotherapeutic regimens</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> OS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mortality at 3 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mortality at 10 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> CR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> ORR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Disease control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Progression or relapse</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kimby 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> <p>(0.67 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> <p>(0.63 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.42</b> </p> <p><b>(1.52 to 7.68)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.70</b> </p> <p><b>(1.30 to 2.23)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66</p> <p>(0.41 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> <p>(0.67 to 1.20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peterson 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> <p>(0.70 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15</p> <p>(0.66 to 2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95</p> <p>(0.74to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> <p>(0.74 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04</p> <p>(0.96 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84</p> <p>(0.63 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03</p> <p>(0.82 to 1.28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unterhalt 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.82</b> </p> <p><b>(1.10 to 3.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02</p> <p>(0.89 to 1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.59</b> </p> <p><b>(0.36 to 0.98)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CR: complete response; NR: not reported; ORR: overall response rate; OS: overall survival</p> </div> </div> <section id="CD008909-sec-0073"> <h5 class="title">Toxicity</h5> <p>Owing to the different regimens used in the ACR and non‐ACR arm we did not proceed with a comparative analysis of adverse events from these trials, although a higher rate of myelosuppression was noted with ACR. <a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a> (cyclophosphamide versus CHOP) have reported two cases of cardiotoxicity only in the ACR arm. </p> </section> </section> <section id="CD008909-sec-0074"> <h4 class="title">Additional analysis ‐ cardiotoxicity (all studies)</h4> <p>Since cardiotoxicity is mainly attributed to anthracyclines we pooled results from all trials reporting cardiotoxicity, regardless of regimen similarity (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>). The pooled RR of ACRs was 4.55 without heterogeneity, but with a very wide 95% CI (0.92 to 22.49) as shown in <a href="./references#CD008909-fig-0029" title="">Analysis 6.1</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008909-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008909-sec-0075"></div> <section id="CD008909-sec-0076"> <h3 class="title" id="CD008909-sec-0076">Summary of main results</h3> <p>This systematic review was undertaken to evaluate the role of anthracyclines in the treatment of patients with FL. Eight RCTs involving a total of 2636 patients were compatible with the inclusion criteria. Over a half of randomized patients had centrally confirmed FL and were evaluable for analysis. Outcomes were reported separately for FL patients in most trials. All patients were therapy‐naive, and most had low‐grade, advanced‐stage FL. We separated the analysis of trials comparing the same chemotherapy with or without an anthracycline and trials comparing different chemotherapies. </p> <p>The following findings emerged.</p> <p> <ol id="CD008909-list-0014"> <li> <p>There was no evidence that anthracyclines improved OS or mortality at three and five years. </p> </li> <li> <p>FL patients treated with ACR had statistically significantly better disease control (e.g. PFS, RD). </p> </li> <li> <p>Subgroup analysis showed that these effects do not necessarily depend on the type of anthracycline. </p> </li> <li> <p>ACR‐treated patients had more side effects than non‐ACR‐treated patients, including myelotoxicity and cardiotoxicity. </p> </li> </ol> </p> </section> <section id="CD008909-sec-0077"> <h3 class="title" id="CD008909-sec-0077">Overall completeness and applicability of evidence</h3> <p>The first‐line treatment of patients with FL is still undetermined. In the US, most patients are treated with R‐CHOP, an ACR. However, there is no proof that ACRs are superior to non‐ACRs. To our knowledge, this is the first systematic review and meta‐analysis trying to answer this important question. </p> <p>The contribution of anthracyclines is best elucidated in trials administering the same regimens in both study arms, as they were designed specifically for this question. We also included trials that involved different regimens in study arms, since anthracyclines are dominant antitumor agents. However, these trials were designed to compare different chemotherapy combinations, where anthracycline is only one of the components. It is impossible, then, to differentiate the effect of anthracyclines from other chemotherapeutic agents, or their combination. Hence, we have separated the analysis of trials according to similarity of chemotherapies in study arms, and outcome measures were summed only from studies that used the same chemotherapy. </p> <p>Even among trials with 'same chemotherapy', regimens were not identical between study arms in three out of five studies. Nonetheless, similarity outweighed the difference (e.g. R‐CVP eight cycles versus R‐CHOP, six cycles in <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>), and we have chosen to sum outcome data. Moreover, since control arms were more intense in all three trials discussed, any benefit of anthracyclines would only underscore their importance. </p> <p>All trials, except for two (<a href="./references#CD008909-bbs2-0005" title="PetersonBA , PetroniGR , FrizzeraG , BarcosM , BloomfieldCD , NissenNI , et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology2003;21(1):5‐15. ">Peterson 2003</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>), randomized patients with NHL, and not specifically FL. However, most patients in these studies had FL, or alternatively, specific data regarding FL patients were reported. Moreover, although diagnosis of FL was usually based on initial pathology, it was confirmed centrally. Thus, even though different classification systems were applied in different trials, it is reasonable to assume that the diagnosis was correct. All FL patients in these trials were previously untreated, and most had advanced‐stage, low‐grade FL. There were not sufficient data to analyze the role of anthracyclines in untreated early‐stage disease, or in persistent or relapsing disease. Subgroup analysis regarding effect of anthracyclines in different grades of FL was not possible. </p> <p>Follow‐up varied between three and 18 years, but most trials reported outcomes at five years, which is reasonable given that until recently the median survival of FL patients was considered to be eight to 10 years. With the introduction of immunotherapy, namely rituximab, longer follow‐up periods are desired. </p> <p>A major limitation to our review is that the trials included were conducted mostly in the pre‐rituximab era. Encouraging data came from <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>, which showed a statistically significant improvement in time to treatment failure with R‐CHOP compared to R‐CVP, at three years' follow‐up. An ongoing trial comparing R‐CHOP to R‐CVP with the addition of R‐maintenance (<a href="./references#CD008909-bbs2-0049" title="NCT00801281 . First‐line R‐CVP vs R‐CHOP induction immunochemotherapy for indolent lymphoma and R maintenance (PLRG4). ClinicalTrials.gov/show/NCT00801281 (accessed 17 April 2013). ">NCT00801281</a>) is expected to further elucidate the role of anthracyclines in the rituximab era. Other trials are conducted to assess the utility of various R‐pixantrone‐based regimens in FL patients. </p> <p>Other important questions that remained unanswered are: the benefit of anthracyclines in high‐risk FL patients, according to FLIPI score; their role in molecular remission and its relevance to prolonged PFS; their effect on FL transformation rate; QoL in patients treated with anthracyclines; and the association between anthracyclines and secondary malignancies. </p> </section> <section id="CD008909-sec-0078"> <h3 class="title" id="CD008909-sec-0078">Quality of the evidence</h3> <p>All trials were RCTs, which is the optimal design for assessment of interventions, yet they were not blinded. All of them were multicenter trials. Hence, we believe that the randomization process was adequate in most trials. </p> <p>In randomized trials, an estimated intervention effect may be biased if some randomized participants are excluded from the analysis. ITT analysis is often recommended as the least biased way to assess an intervention. In our review, most trials claimed to have used ITT analysis, but in fact reported results for fewer patients than were initially randomized (e.g. only for patients with confirmed FL histology). However, the low drop‐out rate in seven trials supports the authors' claim. Protocol violation (<a href="./references#CD008909-bbs2-0006" title="TaylorPR , WhiteJM , PrescottRJ , AngusB , GallowayMJ , JacksonGH , et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia &amp; Lymphoma2006;47(11):2321‐30. ">Taylor 2006</a>) and early stopping of trials (<a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>, and specifically <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a> who did not complete analysis of recruited patients), also weakens the strength of evidence contributed by them. </p> <p>By using HR for analysis of time‐to‐event data, such as OS and disease control measures, we minimized the risk of bias related to measuring death or progression at specific time points. We complemented these results by extracting and calculating RRs for mortality at three and five years, and progression or relapse at three years. </p> <p>We observed a lack of uniformity related to the reporting of treatment‐associated side effects. The most often reported grade 3 and 4 adverse events were myelosuppression, fever, infection, nausea and vomiting, and alopecia. </p> </section> <section id="CD008909-sec-0079"> <h3 class="title" id="CD008909-sec-0079">Potential biases in the review process</h3> <p>Only a few trials were suitable for meta‐analysis of the various outcome measures. Hence, publication of new large trials could substantially change the results of this meta‐analysis. </p> <p>Many trials were conducted and published over a decade ago, which might have introduced bias for several reasons. Over the years different classification systems have been used for hematological malignancies, and there is no certainty that analyzed patients would be regarded as FL patients using present guidelines; methods for staging and the definition of response measures have changed as radiology and laboratory methods improved; standard of care including supportive care have changed over the years, allowing patients to withstand more aggressive therapies. Finally, we could not complete missing data in the older trials. </p> <p>Various protocols, some of which are scarcely administered currently, and different types of anthracyclines have been used making it difficult to assess the role of a specific anthracycline within a given regimen (e.g. doxorubicin in CHOP versus CVP). </p> <p>There was substantial variability in outcome definition for disease control measures. The definition was often partial and did not necessarily comply with the currently published criteria (<a href="./references#CD008909-bbs2-0056" title="ChesonBD , HorningSJ , CoiffierB , ShippMA , FisherRI , ConnorsJM , et al. Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology1999;17(4):1244. ">Cheson 1999</a>; <a href="./references#CD008909-bbs2-0057" title="ChesonBD , PfistnerB , JuweidME , GascoyneRD , SpechtL , HorningSJ , et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology2007;25(5):579‐86. ">Cheson 2007</a>). Death was inconsistently included in trial definitions, and when reported, we had to assume it was death by any cause, and not related to lymphoma specifically. </p> <p>Adverse events were reported in all trials, but inconsistently, and using different measures (i.e. episodes of fever per cycle or per patient; any infection versus severe infection). Therefore, reporting bias is likely. Qualitatively, adverse events were more often reported with ACR. </p> </section> <section id="CD008909-sec-0080"> <h3 class="title" id="CD008909-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge this is the first systematic review and meta‐analysis regarding use of anthracyclines in FL patients. Conflicting results arose from retrospective studies regarding OS and FFS (<a href="./references#CD008909-bbs2-0058" title="DanaBW , DahlbergS , NathwaniBN , ChaseE , ColtmanC , MillerTP , et al. Long‐term follow‐up of patients with low‐grade malignant lymphomas treated with doxorubicin‐based chemotherapy or chemoimmunotherapy. Journal of Clinical Oncology1993;11(4):644‐51. ">Dana 1993</a>; <a href="./references#CD008909-bbs2-0081" title="RigacciL , FedericoM , MartelliM , ZinzaniPL , CavannaL , BellesiG , et al. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leukemia &amp; Lymphoma2003;44(11):1911‐7. ">Rigacci 2003</a>). Most other data came from indirect comparisons, comparing treatment arms to historical cohorts and published literature, indicating an improved response rate with anthracyclines, with inconsistency in relation to other end points (<a href="./references#CD008909-bbs2-0053" title="BrandtL , KimbyE , NygrenP , GlimeliusB . A systematic overview of chemotherapy effects in indolent non‐Hodgkin's lymphoma. Acta Oncologica2001;40(2‐3):213‐23. ">Brandt 2001</a>; <a href="./references#CD008909-bbs2-0051" title="BendandiM . Aiming at a curative strategy for follicular lymphoma. CA: A Cancer Journal for Clinicians2008;58(5):305‐17. ">Bendandi 2008</a>; <a href="./references#CD008909-bbs2-0089" title="TillyH , ZelenetzA . Treatment of follicular lymphoma: current status. Leukemia &amp; Lymphoma2008;49 Suppl 1:7‐17. ">Tilly 2008</a>; <a href="./references#CD008909-bbs2-0092" title="VitoloU , FerreriAJ , MontotoS . Follicular lymphomas. Critical Reviews in Oncology/Hematology2008;66(3):248‐61. ">Vitolo 2008</a>; <a href="./references#CD008909-bbs2-0084" title="SiddharthaG , VijayP . R‐CHOP versus R‐CVP in the treatment of follicular lymphoma: a meta‐analysis and critical appraisal of current literature. Journal of Hematology and Oncology2009;2:14. ">Siddhartha 2009</a>). </p> <p>A previous systematic review of chemotherapy effects in indolent NHL (<a href="./references#CD008909-bbs2-0053" title="BrandtL , KimbyE , NygrenP , GlimeliusB . A systematic overview of chemotherapy effects in indolent non‐Hodgkin's lymphoma. Acta Oncologica2001;40(2‐3):213‐23. ">Brandt 2001</a>) neither focused on FL patients, nor on ACR. Three trials were identified (<a href="./references#CD008909-bbs2-0003" title="KimbyE , BjorkholmM , GahrtonG , GlimeliusB , HagbergH , JohanssonB , et al. Chlorambucil/prednisone vs. CHOP in symptomatic low‐grade non‐Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology1994;5 Suppl 2:67‐71. ">Kimby 1994</a> and <a href="./references#CD008909-bbs2-0007" title="UnterhaltM , HerrmannR , TiemannM , ParwareschR , SteinH , TrumperL , et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low‐grade non‐Hodgkin's lymphoma. German Low‐Grade Lymphoma Study Group. Leukemia1996;10(5):836‐43. ">Unterhalt 1996</a> were included in our review; <a href="./references#CD008909-bbs2-0010" title="Al‐IsmailSA , WhittakerJA , GoughJ . Combination chemotherapy including epirubicin for the management of non‐Hodgkin's lymphoma. European Journal of Cancer &amp; Clinical Oncology1987;23(9):1379‐84. ">Al‐Ismail 1987</a> was excluded), all of which compared different regimens in study arms. The authors concluded that there was no evidence that initial combination therapy prolonged survival, with no remark concerning PFS. </p> <p>Siddhartha (<a href="./references#CD008909-bbs2-0084" title="SiddharthaG , VijayP . R‐CHOP versus R‐CVP in the treatment of follicular lymphoma: a meta‐analysis and critical appraisal of current literature. Journal of Hematology and Oncology2009;2:14. ">Siddhartha 2009</a>) tried to evaluate the difference between R‐CHOP and R‐CVP indirectly, based on trials comparing R‐CHOP versus CHOP and R‐CVP versus CVP. Results suggested better a CR rate with R‐CVP, but higher ORR with R‐CHOP. However, OS and disease control measures were not addressed. </p> <p>Notably, our meta‐analysis is in agreement with almost all aforementioned studies, in that an improvement of disease control measures (i.e. PFS) did not translate into prolonged survival. This contradiction emphasizes the incurable nature of FL, on the one hand, while underscoring the plentitude of effective salvage therapies and improved supportive care, on the other hand. Another factor to consider that the somewhat more intense regimens in the control‐arms of three trials ( <a href="./references#CD008909-bbs2-0002" title="JonesSE , GrozeaPN , MetzEN , HautA , StephensRL , MorrisonFS , et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer1983;51(6):1083‐90. ">Jones 1983</a>; <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>; <a href="./references#CD008909-bbs2-0001" title="FedericoM , LuminariS , DondiA , TucciA , VitoloU , RigacciL , et al. R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology2013;31(12):1506‐13. ">Federico 2013</a>), may have underestimated the benefit of anthracyclines in the treatment of FL. Relatively short follow‐up periods in included trials and the older population of FL patients, may have a role as well. Yet, the place of PFS in directing therapy choices is still debatable. </p> <p>Olin et al (<a href="./references#CD008909-bbs2-0077" title="OlinRL , KanetskyPA , TenHaveTR , NastaSD , SchusterSJ , AndreadisC . Determinants of the optimal first‐line therapy for follicular lymphoma: a decision analysis. American Journal of Hematology2010;85(4):255‐60. ">Olin 2010</a>) have used decision analysis methodology to show that PFS is the most important factor in maximizing quality‐adjusted life years, in advanced‐stage, low‐grade FL patients. Based on their estimates of PFS and QoL from available literature, R‐CHOP is the optimal regimen, followed by R‐Flu, while R‐CVP consistently generated fewer quality‐adjusted life years. QoL assessment could not be assessed in our systematic review. </p> <p>Since there is no consensus on initial treatment of FL, the NLCS published a report of treatment trends of FL in the US (<a href="./references#CD008909-bbs2-0061" title="FriedbergJW , TaylorMD , CerhanJR , FlowersCR , DillonH , FarberCM , et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. Journal of Clinical Oncology2009;27(8):1202‐8. ">Friedberg 2009</a>). Over 50% of patients were treated with R‐CHOP. Moreover, this has become the recommended treatment for patients with grade 3 FL (<a href="./references#CD008909-bbs2-0054" title="BuskeC , GisselbrechtC , GribbenJ , LetaiT , McLaughlinP , WilsonW . Refining the treatment of follicular lymphoma. Leukemia &amp; Lymphoma2008;49 Suppl 1:18‐26. ">Buske 2008</a>). Nonetheless, other authors have expressed doubt regarding the role of anthracyclines (<a href="./references#CD008909-bbs2-0055" title="ChauI , JonesR , CunninghamD , WotherspoonA , MaiseyN , NormanAR , et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front‐line therapy?. British Journal of Cancer2003;89(1):36‐42. ">Chau 2003</a>; <a href="./references#CD008909-bbs2-0075" title="NabhanC . It is follicular... so, why CHOP?. Journal of Clinical Oncology2007;25(7):915‐6. ">Nabhan 2007</a>). </p> <p>The debate concerning best chemotherapy regimen in the rituximab era may seem obsolete, as combination of rituximab with nearly any induction chemotherapy is superior in terms of OS to the same regimen alone (<a href="./references#CD008909-bbs2-0083" title="SchulzH , BohliusJ , SkoetzN , TrelleS , KoberT , ReiserM , et al. Chemotherapy plus Rituximab versus chemotherapy alone for B‐cell non‐Hodgkin's lymphoma. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003805.pub2] ">Schulz 2007</a>). This is reinforced by the fact that maintenance rituximab prolongs OS in patients with relapsed, recurrent, or resistant FL (<a href="./references#CD008909-bbs2-0091" title="VidalL , Gafter‐GviliA , LeiboviciL , ShpilbergO . Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006552.pub2] ">Vidal 2009</a>). However, a clue regarding the importance of anthracyclines in induction therapy for FL came from the international Primary Rituximab and Maintenance (PRIMA) study. This study has shown significant reduction in lymphoma progression with rituximab maintenance as compared with observation. However, in a preplanned Cox regression multivariate analysis, longer PFS was associated with R‐CHOP induction therapy (75% of patients), but could not reach statistical significance for R‐CVP therapy (22% of patients) (<a href="./references#CD008909-bbs2-0082" title="SallesG , SeymourJF , OffnerF , Lopez‐GuillermoA , BeladaD , XerriL , et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet2011;377(9759):42‐51. ">Salles 2011</a>). </p> <p>As the role of anthracyclines with immunotherapy remains to be elucidated, an old drug that has recently re‐emerged puts the necessity of ACR in FL into question. In one large randomized trial comparing bendamustine‐rituximab with R‐CHOP, Rummel et al found the non‐ACR to be superior with respect to PFS and CR and less toxic, with a median follow‐up of 45 months (<a href="./references#CD008909-bbs2-0040" title="RummelMJ , vonGruenhagenU , NiederleN , BalloH , WeidmannE , WelslauM , et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first‐Line‐treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL). Blood (ASH Annual Meeting Abstracts)2008;112:Abstract No 2596. ">Rummel 2009</a>; <a href="./references#CD008909-bbs2-0041" title="RummelMJ , NiederleN , MaschmeyerG , BanatGA , vonGrünhagenU , LosemC , et al. Bendamustine plus rituximab versus CHOP plus rituximab as first‐line treatment for patients with indolent and mantle‐cell lymphomas: an open‐label, multicentre,randomised, phase 3 non‐inferiority trial. Lancet2013;381:1203‐10. ">Rummel 2013</a>). </p> <p>Adverse events were reported more often with ACR, including cardiotoxicity. Various methods have been developed and variably studied in order to reduce them: use of anthracycline‐analogues; continuous infusion of adriamycin (as was also shown in one meta‐analysis, <a href="./references#CD008909-bbs2-0090" title="vanDalenEC , van derPalHJ , CaronHN , KremerLCM . Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD005008.pub3] ">van Dalen 2009</a>); use of liposomal preparations; or administration of various substances including calcium channel blockers and angiotensin receptor blockers (<a href="./references#CD008909-bbs2-0078" title="OutomuroD , GranaDR , AzzatoF , MileiJ . Adriamycin‐induced myocardial toxicity: new solutions for an old problem?. International Journal of Cardiology2007;117(1):6‐15. ">Outomuro 2007</a>). In our meta‐analysis, cardiotoxicity was mostly reported in trials involving doxorubicin. No cardiotoxicity was reported with idarubicin in <a href="./references#CD008909-bbs2-0008" title="ZinzaniPL , MagagnoliM , MorettiL , DeRenzoA , BattistaR , ZaccariaA , et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle‐cell lymphoma. Journal of Clinical Oncology2000;18(4):773‐9. ">Zinzani 2000</a>. Al‐Ismail et al had demonstrated a significantly lower rate of cardiotoxicity from epirubicin, in comparison with adriamycin, in high‐grade lymphoma patients (<a href="./references#CD008909-bbs2-0010" title="Al‐IsmailSA , WhittakerJA , GoughJ . Combination chemotherapy including epirubicin for the management of non‐Hodgkin's lymphoma. European Journal of Cancer &amp; Clinical Oncology1987;23(9):1379‐84. ">Al‐Ismail 1987</a>). Zinzani et al (<a href="./references#CD008909-bbs2-0096" title="ZinzaniPL , PulsoniA , PerrottiA , SoveriniS , ZajaF , DeRenzoA , et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front‐line treatment for patients with follicular lymphoma. Journal of Clinical Oncology2004;22(13):2654‐61. ">Zinzani 2004</a>) compared CHOP with fludarabine‐mitoxantrone (FM), and showed higher CR and molecular remission rate with FM, with fewer adverse events, such as grade 3‐4 neutropenia. However, at 19 months of follow‐up, there was neither survival nor PFS benefit to either regimen. Moreover, no cardiotoxicity was registered. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008909-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008909-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD008909-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.1 Overall survival." data-id="CD008909-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.3 Mortality at 3 years." data-id="CD008909-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.3 Mortality at 3 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.5 Complete response." data-id="CD008909-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.5 Complete response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.7 Disease control." data-id="CD008909-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.7 Disease control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.8 Progression or relapse at 3 years." data-id="CD008909-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.8 Progression or relapse at 3 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.10 Infection." data-id="CD008909-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.10 Infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Comparison of different anthracyclines, outcome: 4.2 Disease control." data-id="CD008909-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Comparison of different anthracyclines, outcome: 4.2 Disease control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 1 Overall survival." data-id="CD008909-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 2 Overall survival with Zinzani." data-id="CD008909-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 2 Overall survival with Zinzani. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 3 Mortality at 3 years." data-id="CD008909-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 3 Mortality at 3 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 4 Mortality at 5 years." data-id="CD008909-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 4 Mortality at 5 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 5 Complete response." data-id="CD008909-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 5 Complete response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 6 Overall response." data-id="CD008909-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 6 Overall response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 7 Disease control." data-id="CD008909-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 7 Disease control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 8 Progression/relapse at 3 years." data-id="CD008909-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 8 Progression/relapse at 3 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 9 Neutropenia grade 3‐4." data-id="CD008909-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 9 Neutropenia grade 3‐4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 10 Infection." data-id="CD008909-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 10 Infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis for allocation concealment, Outcome 1 Overall survival." data-id="CD008909-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis for allocation concealment, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis for allocation concealment, Outcome 2 Disease control." data-id="CD008909-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis for allocation concealment, Outcome 2 Disease control.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis for second randomization, Outcome 1 Disease control." data-id="CD008909-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis for second randomization, Outcome 1 Disease control.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Comparison of different anthracyclines, Outcome 1 Overall survival." data-id="CD008909-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Comparison of different anthracyclines, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-004-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Comparison of different anthracyclines, Outcome 2 Disease control." data-id="CD008909-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Comparison of different anthracyclines, Outcome 2 Disease control.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 1 Overall survival." data-id="CD008909-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 2 Mortality at 3 years." data-id="CD008909-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 2 Mortality at 3 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 3 Complete response." data-id="CD008909-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 3 Complete response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 4 Disease control." data-id="CD008909-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 4 Disease control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008909-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/urn:x-wiley:14651858:media:CD008909:CD008909-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_t/tCD008909-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cardiotoxicity for all studies, Outcome 1 Cardiotoxicity." data-id="CD008909-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Cardiotoxicity for all studies, Outcome 1 Cardiotoxicity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/media/CDSR/CD008909/image_n/nCD008909-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008909-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ACR compared to non‐ACR for treatment of follicular lymphoma in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ACR compared to non‐ACR for treatment of follicular lymphoma in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults receiving treatment for follicular lymphoma<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Aanthracycline<br/> <b>Comparison:</b> no anthracycline same chemotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No anthracycline same chemotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Anthracycline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> number of dead patients<br/> Follow‐up: median 50 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b> <br/> (449 to 631) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.99</b> <br/> (0.77 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality at 3 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> <br/> (174 to 327) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> <br/> (0.67 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>839 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>889 per 1000</b> <br/> (839 to 940) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> <br/> (1 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease control</b> <br/> number of patients with progression<br/> Follow‐up: median 30 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>356 per 1000</b> <br/> (297 to 423) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.65</b> <br/> (0.52 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>759<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression/relapse at 3 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>544 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>397 per 1000</b> <br/> (343 to 463) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.73</b> <br/> (0.63 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neutropenia grade 3‐4</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b> <br/> (277 to 485) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.94</b> <br/> (1.46 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>533<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiotoxicity**</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> <br/> (2 to 40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.55</b> <br/> (0.92 to 22.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1412<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Includes all trials, irrespectively of the comparison ("same chemotherapy"; "different chemotherapy").<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Small number of events<br/> <sup>2</sup> Moderate heterogeneity<br/> <sup>3</sup> Different reporting methods<br/> <sup>4</sup> Not consistently reported<br/> <sup>5</sup> Wide confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ACR compared to non‐ACR for treatment of follicular lymphoma in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008909-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies included in meta‐analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomized</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analyzed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FL analyzed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FL grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Data specific for FL</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Federico 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>504 (333)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2, 3a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For all outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Jones 1983</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226 (146)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2, 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For all outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lepage 1990</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Taylor 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low grade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Zinzani 2000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indolent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kimby 1994</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Peterson 2003</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For all outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unterhalt 1996</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1, 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For some outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2636</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2189</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1520</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>* number of FL patients analyzed in 2 (of 3) arms compared<br/> FL: follicular lymphoma </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies included in meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008909-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Publication status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Same/different intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Anthracycline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Experimental arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Federico 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R‐CVP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R‐CHOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Jones 1983</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CVP‐B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHOP‐B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lepage 1990</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PACOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Taylor 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Idarubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ChD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ChID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Zinzani 2000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Idarubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>F</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kimby 1994</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ch‐D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Peterson 2003</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unterhalt 1996</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mitoxantrone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CVP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PmM</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>* trials with higher non‐anthracycline dose in control‐arm</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008909-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Detailed therapeutic regimens in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Experimental arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Federico 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 rituximab 375 mg/m<sup>2</sup>, d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 40 mg/m<sup>2</sup> PO, 8 cycles, every 21 d </p> <p><i>[Note: more treatment cycles]</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 rituximab 375 mg/m<sup>2</sup>, d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 doxorubicin 50 mg/m<sup>2</sup> IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 100 mg/d PO 6 cycles, every 21 d. Added 2 cycles of rituximab every 21 d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Jones 1983</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐14 cyclophosphamide 125 mg/m<sup>2</sup> PO, d 1, 8 vincristine 1.4 mg/m<sup>2</sup> IV (max 2 mg/dose), d 1‐5 prednisone 100 mg/d PO, d 1, 8 bleomycin 4 mg/m<sup>2</sup> IV. 8 cycles, every 21 d </p> <p><i>[Note: different route of administration for cyclophosphamide; total doses differ for all drugs; cycles are more frequent]</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 doxorubicin 50 mg/m<sup>2</sup> IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 100 mg/d PO, d 1 bleomycin 4 mg/m<sup>2</sup> IV. 8 cycles, every 28 d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lepage 1990</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1, 8 cyclophosphamide 400 mg/m<sup>2</sup> IV, d 1, 8 vincristine 1.4 mg/m<sup>2</sup> , d 1, 14 procarbazine 80 mg/m<sup>2</sup> PO, d 1‐5 prednisone 60 mg/m<sup>2</sup> PO. 6 cycles, every 28 d </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>same + d 1, 8 doxorubicin 20 mg/m<sup>2</sup> IV </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Taylor 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐3 chlorambucil 20 mg/m<sup>2</sup>/d, d 1‐5 dexamethasone 4 mg bd. 6 cycles, every 21 d </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>same + d 1‐3 idarubicin 10 mg/m<sup>2</sup>/d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Zinzani 2000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐5 fludarabine 25 mg/m<sup>2</sup>/d IV. 6 cycles, every 28 d<br/> <i>[Note: total fludarabine dose is higher by 66%]</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐3 fludarabine 25 mg/m<sup>2</sup>/d IV, d 1‐3, d 1 idarubicin 12 mg/m<sup>2</sup> 6 cycles, every 28 d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kimby 1994</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 chlorambucil 0.4 mg/kg PO, d 1‐3 prednisone 75 mg PO every 14 d, for 4‐8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 doxorubicin 50 mg/m<sup>2</sup> IV, d 1 vincristine 2 mg/m<sup>2</sup> IV, d 1‐5 prednisone 50 mg/m<sup>2</sup> PO 4‐8 cycles every 28 d </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Peterson 2003</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1 cyclophosphamide 750 mg/m<sup>2</sup> IV, d 1 doxorubicin 50 mg/m<sup>2</sup> IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 60 mg/m<sup>2</sup> PO, d 1 bleomycin 10 u/m<sup>2</sup> IM every 21 d until complete response and then every 28 d up to 2 years, bleomycin up to 6 cycles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 mg/m<sup>2</sup>/d PO until 2 years from maximal response </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unterhalt 1996</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐5 cyclophosphamide 400 mg/m<sup>2</sup>/d IV, d 1 vincristine 1.4 mg/m<sup>2</sup> (max 2 mg) IV, d 1‐5 prednisone 100 mg/m<sup>2</sup>/d PO 4‐6 induction cycles every 21 d </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>d 1‐5 prednimustine 100 mg/m<sup>2</sup>/d PO, d 1‐2 mitoxantrone 8 mg/m<sup>2</sup>/d IV. 4‐6 induction cycles every 28 d </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>d: day; IM: intramuscular; IV: intravenous; PO: oral</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Detailed therapeutic regimens in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008909-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Outcome measures in trials with different chemotherapeutic regimens</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> OS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mortality at 3 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mortality at 10 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> CR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> ORR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Disease control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Progression or relapse</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kimby 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> <p>(0.67 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> <p>(0.63 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.42</b> </p> <p><b>(1.52 to 7.68)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.70</b> </p> <p><b>(1.30 to 2.23)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66</p> <p>(0.41 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> <p>(0.67 to 1.20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peterson 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> <p>(0.70 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15</p> <p>(0.66 to 2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95</p> <p>(0.74to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> <p>(0.74 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04</p> <p>(0.96 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84</p> <p>(0.63 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03</p> <p>(0.82 to 1.28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unterhalt 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.82</b> </p> <p><b>(1.10 to 3.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02</p> <p>(0.89 to 1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.59</b> </p> <p><b>(0.36 to 0.98)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CR: complete response; NR: not reported; ORR: overall response rate; OS: overall survival</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Outcome measures in trials with different chemotherapeutic regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/full#CD008909-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008909-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anthracycline versus no anthracycline same chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.77, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall survival with Zinzani <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.76, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.67, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality at 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.94, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Overall response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.00, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Disease control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.52, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Progression‐free survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.50, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Response duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.40, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Progression/relapse at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Neutropenia grade 3‐4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.46, 2.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.75, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anthracycline versus no anthracycline same chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008909-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis for allocation concealment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Adequate allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.63, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Unclear allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.67, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adequate allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Unclear allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.41, 0.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis for allocation concealment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008909-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis for second randomization</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Disease control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Second randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.54, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No second randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.40, 0.78]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis for second randomization</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008909-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison of different anthracyclines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.63, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Idarubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.67, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Idarubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.41, 0.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison of different anthracyclines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008909-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Anthracycline versus no anthracycline different chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Disease control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Anthracycline versus no anthracycline different chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008909-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Cardiotoxicity for all studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [0.92, 22.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Same chemotherapy regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.30 [0.66, 28.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Different chemotherapy regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.45 [0.26, 112.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Cardiotoxicity for all studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008909.pub2/references#CD008909-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008909.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008909-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008909-note-0010">فارسی</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008909\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008909\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008909\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008909\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008909\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008909.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008909.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008909.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008909.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008909.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725319380"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008909.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725319384"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008909.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e78568e4f936e',t:'MTc0MDcyNTMxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 